<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id>
      <journal-title>Breast Cancer Research and Treatment</journal-title>
      <issn pub-type="ppub">0167-6806</issn>
      <issn pub-type="epub">1573-7217</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17377838</article-id>
      <article-id pub-id-type="pmc">2217620</article-id>
      <article-id pub-id-type="publisher-id">9556</article-id>
      <article-id pub-id-type="doi">10.1007/s10549-007-9556-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>An overview of prognostic factors for long-term survivors of breast cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Soerjomataram</surname>
            <given-names>Isabelle</given-names>
          </name>
          <address>
            <phone>+31-10-4087005</phone>
            <fax>+31-10-4638474</fax>
            <email>i.soerjomataram@erasmusmc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Louwman</surname>
            <given-names>Marieke W. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ribot</surname>
            <given-names>Jacques G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Roukema</surname>
            <given-names>Jan A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Coebergh</surname>
            <given-names>Jan Willem W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Public Health, Erasmus MC, P.O. Box 2040, Rotterdam, 3000 CA The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Comprehensive Cancer Centre South, P.O. Box 231, 5600 AE Eindhoven, The Netherlands </aff>
        <aff id="Aff3"><label>3</label>Department of Radiotherapy Catharina Hospital, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands </aff>
        <aff id="Aff4"><label>4</label>Department of Surgery, St. Elisabeth Hospital, P.O. Box 90151, 5000 LC Tilburg, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>3</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <volume>107</volume>
      <issue>3</issue>
      <fpage>309</fpage>
      <lpage>330</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>2</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>2</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer Science+Business Media, LLC 2007</copyright-statement>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Numerous studies have examined prognostic factors for survival of breast cancer patients, but relatively few have dealt specifically with 10+-year survivors.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>A review of the PubMed database from 1995 to 2006 was undertaken with the following inclusion criteria: median/mean follow-up time at least 10&#xA0;years; overall survival and/or disease-specific survival known; and relative risk and statistical probability values reported. In addition, we used data from the long-standing Eindhoven Cancer Registry to illustrate survival probability as indicated by various prognostic factors.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>10-year breast cancer survivors showed 90% 5-year relative survival. Tumor size, nodal status and grade remained the most important prognostic factors for long-term survival, although their role decreased over time. Most studies agreed on the long-term prognostic values of MI (mitotic index), LVI (lymphovascular invasion), Her2-positivity, gene profiling and comorbidity for either all or a subgroup of breast cancer patients (node-positive or negative). The roles of age, socioeconomic status, histological type, BRCA and p53 mutation were mixed, often decreasing after correction for stronger prognosticators, thus limiting their clinical value. Local and regional recurrence, metastases and second cancer may substantially impair long-term survival. Healthy lifestyle was consistently related to lower overall mortality.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Effects of traditional prognostic factors persist in the long term and more recent factors need further follow-up. The prognosis for breast cancer patients who have survived at least 10&#xA0;years is favourable and increases over time. Improved long-term survival can be achieved by earlier detection, more effective modern therapy and healthier lifestyle.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Breast cancer</kwd>
        <kwd>Long-term</kwd>
        <kwd>Prognostic factors</kwd>
        <kwd>Survival</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media, LLC. 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Breast cancer (BC) is the most common cancer among women, with a lifetime risk of up to 12% and a risk of death of up to 5% [<xref ref-type="bibr" rid="CR1">1</xref>]. Its incidence has been increasing but after a period of continuous rise in many industrialized countries BC mortality has been stable or has even decreased in the last 10&#x2013;15&#xA0;years [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. The introduction of mass mammographic screening programmes also resulted in earlier detection and diagnosis of small and less aggressive tumours. This, in combination with therapeutic improvements, has led to a substantial increase in BC survivors over the last few decades (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). A long-term survivor is commonly defined as a person who is still alive 5&#xA0;years after cancer diagnosis [<xref ref-type="bibr" rid="CR4">4</xref>]. For BC, the relative survival at 5 and 10&#xA0;years after diagnosis is 88% and 77%, respectively, both substantially higher than the 5-year relative survival of all cancers together (64%) [<xref ref-type="bibr" rid="CR4">4</xref>]. Thus, it seems logical to consider factors known to play an important role in predicting 5-year survival of BC patients and to question their importance in survival 10&#xA0;years after diagnosis and even longer. Furthermore, in recent years major advances in the prognostic value of several molecular markers have been achieved, hence the need to incorporate this data into our current knowledge. Therefore, we have summarized available knowledge on the determinants of survival 10&#xA0;years or more after breast cancer diagnosis. We supported our analyses and considerations with data from the population-based, long-standing Eindhoven cancer registry in the Netherlands.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Proportion of breast cancer patients (3-year moving average) diagnosed between 1973 and 1993 who survived 10&#xA0;years or longer in Southeastern Netherlands</p></caption><graphic position="anchor" xlink:href="10549_2007_9556_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Methods</title>
      <p>We initially searched PubMed, using the search MESH term for &#x2018;breast neoplasms&#x2019; AND &#x2018;prognoses&#x2019; AND &#x2018;long-term&#x2019;. Only papers published in English between 1995 and 2006 (September) which researched female adults (19+&#xA0;years) were included. We retrieved 528 articles and studied the abstracts (sometimes also the methods section). We selected only articles that assess or show the results for those surviving 10&#xA0;years or longer with cohorts having a mean/median follow-up of 10&#xA0;years or longer. If mean/median follow-up time was not reported, we examined the proportion of patients who survived 10&#xA0;years after diagnosis, and this ought to be larger than 50%. If, for a specific topic of interest, no relevant studies with a follow-up of at least 10&#xA0;years were found (such as BRCA mutation or gene profiling, which have been studied only during the last decade), then studies with the longest available follow-up were chosen. Furthermore, the following inclusion criteria were used: overall and/or BC-specific survival was reported; relative risk or hazard rate and statistical probability values were given; at least 250 BC patients included at the beginning of study. We also searched the reference lists collected by this search strategy and selected those that were relevant to both our study question and inclusion criteria. Reviews and books that gave general overviews were also included in the reference list.</p>
      <p>We present data from the Eindhoven Cancer Registry (ECR) to illustrate the role of factors such as age, tumour size, lymph node involvement and time since diagnosis. Within the Netherlands, ECR is unique because it has collected follow-up data since 1970, including clinical aspects of cancer patients. This is a population-based cancer registry covering a population of almost 2.4&#xA0;million people in 2004 [<xref ref-type="bibr" rid="CR5">5</xref>]. Cumulative survival proportion was calculated using the Kaplan Meier method. Relative survival was calculated by comparing the survival of BC patients to the general population.</p>
      <p>Throughout the text the term long-term and/or survival will frequently be mentioned; this corresponds to at least 10-year survival unless otherwise indicated.</p>
    </sec>
    <sec id="Sec3">
      <title>Results and discussions</title>
      <sec id="Sec4">
        <title>Determinants of survival BC 10&#xA0;years or longer</title>
        <sec id="Sec5">
          <title>Patient characteristics</title>
          <sec id="Sec6">
            <title>Age at diagnosis</title>
            <p>Very young women, i.e. younger than 30/35&#xA0;years [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], exhibited a particularly poor survival as do those older than 70 (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Young BC patients were more likely to have a more negative clinical presentation, such as affected lymph nodes, negative for oestrogen receptors, and have large tumour with a high fraction of p53 nuclei and overexpression of c-erb-2 oncoprotein [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. However, current adjuvant treatment seems to diminish the poor prognostic value of young age [<xref ref-type="bibr" rid="CR6">6</xref>]; young women who did not receive adjuvant treatment had a significantly increased risk of dying; those diagnosed at 35&#x2013;39&#xA0;years and &lt;35&#xA0;years had a 1.4 and 2.2&#xA0;higher risk of death, respectively, compared to those of 45&#x2013;49&#xA0;years [<xref ref-type="bibr" rid="CR6">6</xref>]. Older patients exhibited higher mortality rates [<xref ref-type="bibr" rid="CR12">12</xref>], probably because of less extensive treatment (either related to advanced age itself or the presence of serious concomitant diseases (comorbidity)) [<xref ref-type="bibr" rid="CR13">13</xref>].<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Relative survival of breast cancer patients (n: 13,279) diagnosed in 1990&#x2013;2002 and followed until 2004, according to age at diagnosis in southeastern Netherlands</p></caption><graphic position="anchor" xlink:href="10549_2007_9556_Fig2_HTML" id="MO2"/></fig></p>
          </sec>
          <sec id="Sec7">
            <title>Comorbidity</title>
            <p>Concurrent health conditions (comorbidity) at the time of BC diagnosis have a significant impact on early [<xref ref-type="bibr" rid="CR13">13</xref>] as well as long-term survival of BC patients [<xref ref-type="bibr" rid="CR12">12</xref>]. The most prevalent conditions were cardiovascular disease (7%), previous cancer (7%) and diabetes mellitus (6%), all becoming more common with increasing age [<xref ref-type="bibr" rid="CR13">13</xref>]. Compared to those without comorbidity whose 5-year relative survival was 87%, those with diabetes mellitus or cardiovascular disease represented 78% and 83% of the respective survival estimates [<xref ref-type="bibr" rid="CR13">13</xref>]. Patients with severe comorbidity exhibited a 2.7&#x2013;3.4 higher risk of death in 10&#xA0;years compared to those without comorbidity [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p>
          </sec>
          <sec id="Sec8">
            <title>Period of diagnosis</title>
            <p>Access to care and treatment of BC has improved over time in most industrialized countries, which is reflected in the higher long-term survival of BC cases across all age groups and the tumour characteristics of those diagnosed more recently [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR18">18</xref>]. In Finland, relative survival 10&#xA0;years after diagnosis among patients younger than 50&#xA0;years increased from 49% for those diagnosed in 1953&#x2013;1959 to 68% for the 1983&#x2013;1989 cohort [<xref ref-type="bibr" rid="CR15">15</xref>]. Furthermore, 60% of node-positive BC patients diagnosed in 1978&#x2013;1979 in Italy survived 10&#xA0;years or longer compared to the 50% probability 10-year survival for those diagnosed in 1968&#x2013;1969 [<xref ref-type="bibr" rid="CR17">17</xref>]. In addition, changes in BC diagnosis, e.g. screening[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] and better staging [<xref ref-type="bibr" rid="CR17">17</xref>], may partly be responsible for the observed increase in the proportion of survivors.</p>
          </sec>
          <sec id="Sec9">
            <title>Time after diagnosis</title>
            <p>The longer a woman survives BC the more the prognosis improves, illustrated by conditional survival [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Probably the subgroup of patients who survived longer had less aggressive tumours due to a different genetic make-up or better life-style. In Australia, 79% of women with localized BC survived 10&#xA0;years after diagnosis, yet among those still alive 5&#xA0;years after diagnosis 84% had a 10-year survival [<xref ref-type="bibr" rid="CR16">16</xref>]. The respective values for regional vs. advanced BC were 53% and 68% [<xref ref-type="bibr" rid="CR16">16</xref>]. Unlike other cancers, relative conditional survival remained stable below 100% after 12&#xA0;years of survival and decreased again after about 19&#xA0;years (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>]. This may be a consequence of late recurrences and metastases, second cancers or late side-effects of treatment [<xref ref-type="bibr" rid="CR23">23</xref>].<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Conditional 5-year relative survival (calculated using period analysis [<xref ref-type="bibr" rid="CR22">22</xref>] of breast cancer patients diagnosed in southern Netherlands in 1985&#x2013;2002 and followed until 2004, according to age. (<italic>Dashed line</italic>): diagnosed at 25&#x2013;49&#xA0;years, (<italic>solid line</italic>): diagnosed at 50&#x2013;74&#xA0;years</p></caption><graphic position="anchor" xlink:href="10549_2007_9556_Fig3_HTML" id="MO3"/></fig></p>
          </sec>
          <sec id="Sec10">
            <title>Socioeconomic status (SES) and race</title>
            <p>A population-based study of BC patients diagnosed in 1968&#x2013;1999 in France showed a diminishing role of SES on excess mortality among women with BC over these periods [<xref ref-type="bibr" rid="CR24">24</xref>]. Long-term follow-up studies reported that women with BC from low social classes had a 20&#x2013;50% poorer survival compared to patients from higher social classes [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], although others contradicted this [<xref ref-type="bibr" rid="CR27">27</xref>]. Low SES patients were more likely to be diagnosed at a later stage, had more aggressive tumour characteristics and might have received sub-optimal treatment. However, differences in these prognostic factors did not fully explain the variation in survival according to social class [<xref ref-type="bibr" rid="CR25">25</xref>]. This is also the case when breast cancer survival is studied according to race/ethnicity. Ten years after treatment 58% of African Americans were still alive compared to 66% of the white Americans. After adjusting for other prognostic factors, 41% excess mortality from all causes was still observed among African Americans compared to caucasians [<xref ref-type="bibr" rid="CR28">28</xref>]. This suggests other residual factors such as lifestyle (higher body weight was observed among African Americans), comorbidity [<xref ref-type="bibr" rid="CR14">14</xref>], genetics or variation in the delivery of treatment, which influence outcome beyond variation in tumour aggressiveness [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
          </sec>
        </sec>
        <sec id="Sec11">
          <title>Tumour-related characteristics</title>
          <sec id="Sec12">
            <title>Tumour size</title>
            <p>Tumour size is one of the strongest prognostic indicators (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], even after 20&#xA0;years of follow-up [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. A larger tumour has been related to more positive lymph nodes [<xref ref-type="bibr" rid="CR32">32</xref>], thus their interaction further influences the survival from BC. Nonetheless, the independence of survival by node status is shown by the lower 10-year overall survival rate found for node-negative patients with a tumour of 2&#x2013;5&#xA0;cm compared to those with a tumour smaller than 1&#xA0;cm, 66% vs. 79%, respectively [<xref ref-type="bibr" rid="CR33">33</xref>].<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970&#x2013;1994 and followed until 2004, according to tumor size (based on pathological diagnosis). &#x25A0; tumor size: &lt;2&#xA0;cm (n: 3263) &#x2022; tumor size: 2&#x2013;5&#xA0;cm (n: 3420) &#x25B4; tumor size: &gt;5&#xA0;cm (n: 474) <bold>x</bold> tumor size: involvement of skin (n: 1133) and unknown/not applicable tumor size: 1410</p></caption><graphic position="anchor" xlink:href="10549_2007_9556_Fig4_HTML" id="MO4"/></fig></p>
          </sec>
          <sec id="Sec13">
            <title>Histological type</title>
            <p>The prognostic value of histological type can be grouped into four: excellent, good, poor and very poor prognosis [<xref ref-type="bibr" rid="CR34">34</xref>]. BC with an excellent prognosis, such as invasive cribriform, tubular [<xref ref-type="bibr" rid="CR35">35</xref>], tubulo-lobular and mucinous [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] showed &gt;80% survival at 10&#xA0;years [<xref ref-type="bibr" rid="CR9">9</xref>]. Tubular mixed, mixed ductal with special type, atypical medullary [<xref ref-type="bibr" rid="CR38">38</xref>] and alveolar lobular carcinoma have a good prognosis with a 60&#x2013;80% 10-year survival. Those with invasive papillary, classic lobular and medullary cancers have a worse prognosis. Finally, 10-year survival among those with ductal, solid lobular, mixed ductal and lobular carcinoma is below 50% [<xref ref-type="bibr" rid="CR34">34</xref>]. In most populations infiltrating ductal carcinoma covers about 70% of all diagnoses [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Inflammatory BC has a particularly poor prognosis: about 30% survived 10&#xA0;years [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
          </sec>
          <sec id="Sec14">
            <title>Histological grade</title>
            <p>The most widely used grading systems are Scarff-Bloom-Richardson classification, Fisher grading nuclear system and Nottingham Combined Histologic Grade (NCHG) [<xref ref-type="bibr" rid="CR41">41</xref>]. The validity of grading has been subjected to inter-observer reproducibility and subjectivity [<xref ref-type="bibr" rid="CR42">42</xref>]. However, higher grades have been quite consistently associated with lower long-term survival [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#x2013;<xref ref-type="bibr" rid="CR45">45</xref>]. Depending on other prognostic factors, such as nodal status or tumour size [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], cumulative survival among patients with the lowest score was 90&#x2013;94% 10&#xA0;years after diagnosis and 30&#x2013;78% among those with the highest score [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p>
          </sec>
          <sec id="Sec15">
            <title>Regional lymph node involvement</title>
            <p>Lymph node involvement is a valuable indicator of long-term survival (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Node- positive patients have about a 4&#x2013;8 times higher mortality than those without nodal involvement [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The more nodes involved the worse the prognosis. Prognosis for patients with 10 or more involved axillary nodes showed 70% more deaths at 10&#xA0;years than for those with 1&#x2013;3 involved nodes [<xref ref-type="bibr" rid="CR32">32</xref>]. The survival of node-positive patients improved due to better staging procedures and application of systemic treatment [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].<fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970&#x2013;1994 and followed until 2004, according to nodal status (based on pathological diagnosis). &#x25A0; node negative (n: 4452) &#x2022; node status: 1&#x2013;3 positive nodes (n: 3266) &#x25B4; node status: 4&#x2013;9 positive nodes (n: 255) <bold>x</bold> node status: 10+ positive nodes (n: 189), unknown/not applicable node status: 1538</p></caption><graphic position="anchor" xlink:href="10549_2007_9556_Fig5_HTML" id="MO5"/></fig></p>
          </sec>
          <sec id="Sec16">
            <title>Lymphovascular invasion (LVI) and molecular markers of tumours angiogenesis</title>
            <p>At the St. Gallen meeting in 2005, LVI was added to the prognostics for node-negative patients [<xref ref-type="bibr" rid="CR51">51</xref>]. Compared to patients having no LVI, a 60% higher BC mortality was observed for node-negative BC patients having positive LVI [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], although others did not observe the independent role of LVI [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. In this line of research, studies have also focused on the value of microvessel density [<xref ref-type="bibr" rid="CR44">44</xref>], blood invasion (BVI) [<xref ref-type="bibr" rid="CR54">54</xref>] and markers of angiogenesis (VEGFR (vascular endothelial growth factor receptor), CD105, Tie-2) [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] in predicting long-term survival of BC patients, although the results are still conflicting.</p>
          </sec>
          <sec id="Sec17">
            <title>Grouped prognostic factors</title>
            <p>Some of the prognostic factors have been combined into a prognostic index, such as the TNM classification and also the more current Nottingham Prognostic Index (NPI), both highly predictive for estimating long-term survival [<xref ref-type="bibr" rid="CR41">41</xref>]. TNM staging consists of information on primary tumour size, involvement of the regional lymph node and the presence of distant metastasis. Only 53% of patients with regional or locally advanced BC had survived 10&#xA0;years after diagnosis compared to 79% of those with localised BC [<xref ref-type="bibr" rid="CR16">16</xref>]. Patients with metastasis (stage: M1) at diagnosis exhibited very poor 10-year survival (3.4%) [<xref ref-type="bibr" rid="CR57">57</xref>].<fig id="Fig6"><label>Fig.&#xA0;6</label><caption><p>Cumulative survival of breast cancer patients diagnosed in southern Netherlands in 1970&#x2013;1994 and followed-up until 2004, according to second cancer. Follow-up for patients with second cancer begins at the date of second cancer diagnosis. &#x25A0; no second cancer (n: 8137) &#x2022; second breast cancer (n: 744) &#x25B4; second non-breast cancer (n: 819)</p></caption><graphic position="anchor" xlink:href="10549_2007_9556_Fig6_HTML" id="MO6"/></fig></p>
            <p>Tumour size, grade and lymph node status make up the NPI [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. In a large series of 2879 BC patients, 10-year survival proportion was 85% for those with the lowest NPI score and 19% for those with the highest score [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
          </sec>
        </sec>
        <sec id="Sec18">
          <title>Recurrence, metastasis and second cancer</title>
          <p>Patients with recurrent, metastasized or second cancer generally exhibited lower long-term survival than those without [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR58">58</xref>&#x2013;<xref ref-type="bibr" rid="CR61">61</xref>]. Ten years after surgery, the probability for survival for another 10&#xA0;years, thus 20&#xA0;years after diagnosis, for node-negative patients aged &#x2265;45&#xA0;years, tumour &#x2264;1&#xA0;cm, grade 1 and without a recurrence or metastasis was 0.89. If a recurrence occurred, the probability of being alive at 20&#xA0;years dropped to 0.72. If a metastasis was observed the probability of survival was only 0.18 [<xref ref-type="bibr" rid="CR21">21</xref>]. The prognosis decreases with larger primary tumour size, nodal involvement [<xref ref-type="bibr" rid="CR62">62</xref>], higher grade,[<xref ref-type="bibr" rid="CR21">21</xref>] early recurrence (within 5&#xA0;years of surgery)[<xref ref-type="bibr" rid="CR63">63</xref>], location of recurrence (regional rather than local ipsilateral) [<xref ref-type="bibr" rid="CR59">59</xref>] and inadequate primary cancer treatment [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. In the dataset of the ECR, overall survival was better for women without second primary tumours than for women who developed a new primary cancer (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). Only 68% of early BC patients with second malignancies had survived 10&#xA0;years of follow-up compared to 78% of those without multiple cancers [<xref ref-type="bibr" rid="CR65">65</xref>]. Younger BC patients are reported to have poorer survival and a higher risk of second cancer [<xref ref-type="bibr" rid="CR59">59</xref>]. Corrected for race and grade, women in the 20-29&#xA0;year old category who had a second BC had a probability of 10-year survival probability of only 23% compared to 57% for those without multiple cancers.</p>
        </sec>
        <sec id="Sec19">
          <title>Other tumour markers</title>
          <sec id="Sec20">
            <title>Hormone receptors</title>
            <p>The presence of hormone receptors such as oestrogen (ER) and progesterone (PR) receptors predicts the long-term outcome of hormonal therapy [<xref ref-type="bibr" rid="CR66">66</xref>], thus they have been more commonly used as a predictive marker rather than as a prognostic marker. Thus given a particular treatment, e.g. tamoxifen, ER-positive patients have a considerably better prognosis than ER-negative patients. The prognostic value is weak [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR43">43</xref>] or negligible [<xref ref-type="bibr" rid="CR37">37</xref>], particularly in the early years after diagnosis [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
          </sec>
          <sec id="Sec21">
            <title>HER-2 expression</title>
            <p>Node-positive patients with BC cells showing amplification of the gene for human epidermal growth factor receptor type 2 (HER2), and/or overexpression of its product had a lower 10-year overall survival proportion, 50% versus 65% for those without HER2 amplification [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. After 10&#xA0;years the difference in survival persisted, although it became somewhat smaller[<xref ref-type="bibr" rid="CR17">17</xref>]. Tumours that overexpress HER2 are more likely to contain p53 abnormalities, to be hormone receptor- and bcl-2-negative and to have lymphoid infiltration and a high mitotic index, all known to be markers of poor prognosis for BC [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. As for patients with node- negative tumours, HER2 did not seem to affect long-term survival significantly [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. HER-2 expression has been valuable in predicting treatment responses to trastuzumab, certain endocrine therapies and chemotherapy, adding to it&#x2019;s role as a predictive marker [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
          </sec>
          <sec id="Sec22">
            <title>Mitotic Activity Index (MAI)</title>
            <p>MAI is an indicator of tumour proliferative activity that represents the mitotic activity in a given area of the tumour. Combined with another prognostic factor (NCHG), MAI has proven to be an accurate tool for assessment of long-term survival [<xref ref-type="bibr" rid="CR48">48</xref>]. In a population-based study women with node-negative tumours &lt;5&#xA0;cm and a MAI &#x2265;10 exhibited 80% survival at 10&#xA0;years compared to 90% for an MAI &lt;10 [<xref ref-type="bibr" rid="CR71">71</xref>].</p>
          </sec>
          <sec id="Sec23">
            <title>Gene expression profile</title>
            <p>A very promising new finding is the microarrays method, in which a set of intrinsic genes is clustered and segregated into major subgroups; BC with a good and poor prognosis profile is correlated to the probability of distant metastases [<xref ref-type="bibr" rid="CR72">72</xref>] or a tumour with basal or luminal characteristics which are strongly associated with ER status [<xref ref-type="bibr" rid="CR73">73</xref>]. In a study of 295 patients diagnosed with stage I or II breast cancer, those classified as having a good prognosis profile had a 95% overall 10-year survival rate compared to 55% for those with a poor profile [<xref ref-type="bibr" rid="CR74">74</xref>]. This classification predicted outcome regardless of the nodal status, implying that more accurate criteria have become available for administering adjuvant systemic treatment.</p>
          </sec>
          <sec id="Sec24">
            <title>Various molecular markers</title>
            <p>BRCA1 &amp; 2 mutations were first identified in 1994 and are BC risk factors for some specific groups [<xref ref-type="bibr" rid="CR75">75</xref>]. Their role as prognostic indicator for long-term (more than 10-year) survival has not yet been established. A study of 496 women (median follow-up: 116&#xA0;months), 56 of whom (11%) carried a BRCA1/BRCA2 mutation, showed worse BC-specific survival for women with BRCA1 mutations than for those without (62% at 10&#xA0;years versus 86%; <italic>P</italic>&#xA0;&lt;&#xA0;0.0001), but not for women with the BRCA2 mutation [<xref ref-type="bibr" rid="CR76">76</xref>]. However, another study which compared patients from BRCA1, BRCA2 and non-BRCA1/2 families as well as sporadic cases did not confirm the prognostic role of BRCA1/2 [<xref ref-type="bibr" rid="CR77">77</xref>].</p>
            <p>Long-term follow-up studies have not demonstrated an independent effect of p53 mutations on long-term survival. The P53 mutation was related to a poor clinical profile for patients, hence in multivariate analysis its role on survival diminished [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>].</p>
            <p>A high level of tissue urokinase-type plasminogen activator (uPA) and its inhibitors has been correlated with poor outcome for node-negative and node-positive patients. Those having the highest level of uPA have a five times greater risk of dying from BC compared to those with the lowest level [<xref ref-type="bibr" rid="CR69">69</xref>]. Other factors such as Ki67 (MIB-1), cathepsin-D, DNA ploidy and S-phase have been suggested as prognosticators of survival, with conflicting results, particularly among long-term survivors. Their use in general clinical settings is therefore not recommended [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>].</p>
          </sec>
        </sec>
        <sec id="Sec25">
          <title>Miscellaneous</title>
          <sec id="Sec26">
            <title>Lifestyle</title>
            <p>Generally, increased death rates due to BC (13&#x2013;20%), other causes (49&#x2013;86%) and all causes (14&#x2013;70%) have been observed among obese patients [<xref ref-type="bibr" rid="CR82">82</xref>&#x2013;<xref ref-type="bibr" rid="CR85">85</xref>]. Normal body weight tended be more beneficial in death from other causes than from BC: [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] 9.5% of obese patients died from non-BC causes compared to 6.4% and 5.8%, respectively, of the normal or intermediate groups [<xref ref-type="bibr" rid="CR82">82</xref>]. Obesity was also related to a 2-fold increased risk of postmenopausal contralateral BC and a 60% higher occurrence of second other cancers [<xref ref-type="bibr" rid="CR84">84</xref>]. Therefore, normal weight may reduce the risk of second post-menopausal BC, second other cancers and overall mortality [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR86">86</xref>].</p>
            <p>Compared with women who engaged in less than 9 metabolic equivalent task (MET)-hours per week of activity, women who engaged in 9 or more MET-hours per week had a 40% lower risk of death from all causes, translating into a 6% absolute (unadjusted) reduction in mortality [<xref ref-type="bibr" rid="CR87">87</xref>], which emphasizes the need to advise physical activity.</p>
            <p>So far, although studies have not convincingly shown the positive influence of eating fruit, vegetables and soy bean on long-term BC survival [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR88">88</xref>], diets high in fruits, vegetables, legumes, poultry, and fish and a low intake of red meat, desserts and high fat dairy products are likely to protect against mortality from non-BC causes [<xref ref-type="bibr" rid="CR89">89</xref>].</p>
          </sec>
        </sec>
      </sec>
      <sec id="Sec27">
        <title>Modification of BC&#x2019;s prognostic factors</title>
        <p>Various studies have questioned the role of BC risk factors in determining the biological tumour features as mentioned above. Indeed, BC risk factors seem to differ according to histological type, grade, size, nodal status and ER/PR receptor status [<xref ref-type="bibr" rid="CR90">90</xref>&#x2013;<xref ref-type="bibr" rid="CR93">93</xref>]. For example, excessive alcohol intake and obesity increased the risk for the development of ER-positive tumours [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. As for late age at first full-term birth and obesity are related to an increased risk of large tumours [<xref ref-type="bibr" rid="CR91">91</xref>]. Hence, risk factors for BC may also affect breast biology and clinical behaviour, thus also BC prognosis.</p>
      </sec>
      <sec id="Sec28">
        <title>Changing importance of prognostic factors over time after diagnosis</title>
        <p>Commonly, the value of prognostic factors decreases depending on the length of the follow-up period [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Survival curves according to prognostic factors usually show a large drop in survival for all stages during the first 5&#xA0;years; afterwards the curve stabilizes. Studies agreed on the long-lasting influence of tumour size at diagnosis on survival, albeit attenuating over time [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Grade, nodal status and metastases were also valuable in predicting survival up to 20&#xA0;years after diagnosis [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Although, others have reported that 10&#xA0;years after diagnosis only tumour size [<xref ref-type="bibr" rid="CR94">94</xref>] or nodal status [<xref ref-type="bibr" rid="CR8">8</xref>] or old age [<xref ref-type="bibr" rid="CR8">8</xref>] remained as an independent predictor of long-term survival. Similarly, ER/PR status and MAI only had a significant prognostic role in the first 5&#x2013;10&#xA0;years after diagnosis [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Because even 10&#xA0;years after BC diagnosis the probability of survival for BC patients does not seem to reach that of the general population, the role of other prognostic factors in determining survival for long-term survivors still needs to be determined.</p>
      </sec>
      <sec id="Sec29">
        <title>The role of early detection</title>
        <p>Increased awareness among women and improvement in diagnostic procedures have enabled earlier and better detection of BC. Trials on population screening have reported 21&#x2013;29% reduction in BC mortality for women invited for screening within 14&#x2013;16&#xA0;years of follow-up [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Screening identified tumours at an early stage consequently, survival improved [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Screening also identified patients with slowly growing tumours who might receive unnecessarily aggressive cancer treatment. Thus, Joensuu et&#xA0;al. [<xref ref-type="bibr" rid="CR100">100</xref>] examined recurrence rates among patients detected by screening compared to those detected outside screening. After adjusting for tumour aggressiveness (tumour size, nodal status, grade, age, treatment, PR status, HER-2), hence eliminating bias towards detection of indolent cancers (length bias), the benefit of screening for the prognosis for BC patients remained evident.[<xref ref-type="bibr" rid="CR100">100</xref>] This suggests that other factors explain the indolent behaviour of BC detected by screening. Hence, until this factor is established, detection mode should probably be considered as a prognostic factor and thus be taken into account in patient management.</p>
      </sec>
      <sec id="Sec30">
        <title>The role of treatment</title>
        <p>Improvement in BC treatment has undoubtedly also increased the long-term survival of BC patients [<xref ref-type="bibr" rid="CR101">101</xref>], as reflected by the improved overall survival across all BC stages [<xref ref-type="bibr" rid="CR16">16</xref>]. Using historical data from population-based studies in periods when effective treatment was not available, it was estimated that without treatment only 4% of BC patients would survive 10&#xA0;years or longer [<xref ref-type="bibr" rid="CR102">102</xref>]. BC treatment guidelines have been modified continuously in the last 28&#xA0;years, tailored to most of the prognosticators mentioned earlier [<xref ref-type="bibr" rid="CR51">51</xref>]. Effectiveness of various treatment modalities has been summarized by others who conclude that radiation, chemotherapy and hormonal therapy may reduce long-term mortality by up to 57% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR103">103</xref>&#x2013;<xref ref-type="bibr" rid="CR105">105</xref>]. Emerging new therapeutic approaches using a monoclonal antibody directed against HER-2 have yielded improved short-term survival for advanced stage [<xref ref-type="bibr" rid="CR106">106</xref>] as well as operable BC patients [<xref ref-type="bibr" rid="CR107">107</xref>]. Quality of treatment as indicated by loco-regional failure [<xref ref-type="bibr" rid="CR108">108</xref>], surgeon workload [<xref ref-type="bibr" rid="CR109">109</xref>] or hospital volume [<xref ref-type="bibr" rid="CR110">110</xref>], may affect survival although its role on long-term survival still needs confirmation. In conclusion, on the one hand we have observed a shift in stage towards less aggressive cancers; on the other hand, better and more (systemic) treatment has become available, leading to improved survival for BC patients.</p>
      </sec>
    </sec>
    <sec id="Sec31">
      <title>Conclusion</title>
      <p>The prognosis of BC has become relatively good, with current 10-year relative survival about 70% in most western populations [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR111">111</xref>], especially if up-to-date statistical method such as the period analyses is used [<xref ref-type="bibr" rid="CR111">111</xref>] (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Even better, the longer patients survive their BC the higher their survival chance [<xref ref-type="bibr" rid="CR16">16</xref>]. Our review shows conventional prognostic factors of survival, such as tumour size, lymph node status and grade, remain the most important determinants of 10-year survival for BC patients (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Most studies agreed on the value of MAI and LVI for prediction of long-term survival. The influence of host factors including age, race/ethnicity or socio-economic factors and tumour-related factors such as histological type and angiogenesis diminishes after correction for other factors. For most recent markers such as Her2, gene profiling, p53 mutation and uPA level longer follow-up is needed. Recurrence, metastases and a second cancer double the burden of disease thus increase risk of mortality. Similarly, co-occurrence with other diseases is in no doubt decrease survival.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Overview of studies reporting long-term prognostic factors for breast cancer (BC) patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">No.</th><th align="left">Author, year</th><th align="left">No. of patients</th><th align="left">Mean/median follow-up (yrs)</th><th align="left">Univariate (UV) analysis significant</th><th align="left">Multivariate (UV) analysis significant</th><th align="left">Not significant</th><th align="left">Remarks</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Haerslev and Jacobsen 1995 [<xref ref-type="bibr" rid="CR70">70</xref>]<sup>a</sup></td><td align="left">490</td><td align="left">10.6</td><td align="left">MS, T, N, Htyp,<break/> MI, G, PR, Her2</td><td align="left">All patients: N &amp; PR<break/> In N+: MI &amp; PR<break/> In N-: MS &amp; G</td><td align="left">Her2</td><td align="left">Overall survival was measured. P53 was related to absence of tubular formation, high G, ER-negative, high PCNA (proliferating cell nuclear antigen) score</td></tr><tr><td align="left">2</td><td align="left">Pietilainen 1995 [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="left">392</td><td align="left">11.1</td><td align="left">P53, N, T, Htyp, tubular formation, intraductal growth, margin formation, necrosis, DNA ploidy, S-phase fraction</td><td align="left">All patients: N, T, MI<break/> In N+: T, MI<break/> In N&#x2212;: T, p53, G</td><td align="left"/><td align="left">Overall survival was measured. P53 is related to younger age, MI, AI, G, nuclear pleomorphism</td></tr><tr><td align="left">3</td><td align="left">Haerslev 1995 [<xref ref-type="bibr" rid="CR79">79</xref>]<sup>a</sup></td><td align="left">490</td><td align="left">11</td><td align="left">PCNA</td><td align="left">T, G, PR</td><td align="left">Her2 &amp; PCNA (Proliferating cell nuclear antigen)</td><td align="left">Overall survival was measured. PR was only an independent factor in N-positive pts. Her2 &amp; PCNA were related to more positive N, higher G, ER-/PR-negative</td></tr><tr><td align="left">4</td><td align="left">Gamel 1996 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">163,808</td><td align="left">NR. Range 1mos-19&#xA0;yrs</td><td align="left">Histological type by stage (localized &amp; regional BC)</td><td align="left"/><td align="left"/><td align="left">Breast cancer specific survival was measured</td></tr><tr><td align="left">5</td><td align="left">West 1996 [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">1196</td><td align="left">NR. Diagnosed: 1973&#x2013;1986. End FU: 1994.</td><td align="left">Comorbidity</td><td align="left">Level of comorbidity</td><td align="left">Adjusted for age, race, stage, N, therapy. Values for these factors were not shown</td><td align="left">Overall survival was measured. Charlson comorbidity index was used. There is no difference in the significance of comorbidity on survival of Caucasians and African American (AA)</td></tr><tr><td align="left">6</td><td align="left">Haerslev 1996 [<xref ref-type="bibr" rid="CR112">112</xref>]<sup>a</sup></td><td align="left">487</td><td align="left">&gt;10</td><td align="left">Ki-67, PCNA</td><td align="left">T, G, PR</td><td align="left">Ki-67 &amp; PCNA.</td><td align="left">Overall survival was measured. PR only an independent factor for N+ patients. Ki-67 was related to T, MI, G</td></tr><tr><td align="left">7</td><td align="left">Northridge 1997 [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">Mucinous BC: 4082. Infiltrating duct BC: 139,154</td><td align="left">NR. Diagnosed: 1973&#x2013;1990</td><td align="left"/><td align="left">HTyp, period of diagnosis, Stage, G</td><td align="left">Age</td><td align="left">Breast cancer specific survival was measured</td></tr><tr><td align="left">8</td><td align="left">Kollias 1997 [<xref ref-type="bibr" rid="CR11">11</xref>]<sup>a</sup></td><td align="left">2879 age&#xA0;&#x2264;70, T &lt;5cm</td><td align="left">&gt;10</td><td align="left">Age &lt;35, NPI</td><td align="left">T, G, N</td><td align="left">Age</td><td align="left">Overall survival was measured. Younger than 35&#xA0;yrs had higher grade, more LVI and worse NPI group. After 10yrs NPI did not change OS</td></tr><tr><td align="left">9</td><td align="left">Zahl and Tretli 1997 [<xref ref-type="bibr" rid="CR95">95</xref>]</td><td align="left">8802 age &lt;70</td><td align="left">Diagnosed: 1965&#x2013;74. End FU: 1991</td><td align="left">Survival categorized by age, stage and follow-up time</td><td align="left"/><td align="left"/><td align="left">Excess hazard from breast cancer was measured. After 8&#xA0;yrs being younger than 35&#xA0;does not influence survival. Stage was an important prognosticator up to 20&#xA0;yrs</td></tr><tr><td align="left">10</td><td align="left">Pinder 1998 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">465</td><td align="left">12</td><td align="left">N by grade, Treatment by grade</td><td align="left"/><td align="left"/><td align="left">Overall survival was measured. The study aimed to confirm value of Nottingham grading system for survival. N+G3 patients benefited from prolonged chemotherapy</td></tr><tr><td align="left">11</td><td align="left">Gaffney 1998 [<xref ref-type="bibr" rid="CR113">113</xref>]</td><td align="left">BRCA1: 30<break/>BRCA2: 20<break/> Control: 18278<break/> BC pts</td><td align="left">BRCA1: 9.8<break/> BRCA2: 7.5<break/> Control: NR</td><td align="left"/><td align="left"/><td align="left">BRCA1 vs. BRCA2 vs. control</td><td align="left">Overall survival was measured<break/> Case and control were matched for date of birth, date of diagnosis and tumour size. Patients with BRCA+ were younger. Patients with BRCA1 had higher grade</td></tr><tr><td align="left">12</td><td align="left">Wojcik 1998 [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">6577 patients<break/> Whites: 5879<break/> African American (AA): 698</td><td align="left">At 10&#xA0;yrs 59&#x2013;67% patients were alive</td><td align="left">Race, G, N, T, stage, waiting time, smoking, being a widow, having other family as dependent</td><td align="left">Race, age, stage</td><td align="left">UV: alcohol, family history</td><td align="left">Overall survival was measured. AA is more likely to be younger at diagnosis, have larger tumour, higher stage and more lymph nodes</td></tr><tr><td align="left">13</td><td align="left">Mansi 1999 [<xref ref-type="bibr" rid="CR114">114</xref>]</td><td align="left">350</td><td align="left">12.5</td><td align="left">Bone marrow micrometastases</td><td align="left">N, T</td><td align="left">Bone marrow micrometastases, LVI</td><td align="left">Overall and breast cancer-specific survival was measured. Bone marrow metastases may be useful as prognostic factor for BC pts without information on T and N</td></tr><tr><td align="left">14</td><td align="left">Kollias 1999 [<xref ref-type="bibr" rid="CR46">46</xref>]<sup>a</sup></td><td align="left">319 T &#x2264;1cm</td><td align="left">&gt;10</td><td align="left">G, N, LVI, NPI</td><td align="left">G, N</td><td align="left">LVI</td><td align="left">Overall survival was measured</td></tr><tr><td align="left">15</td><td align="left">Tabar 1999 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">2468</td><td align="left">NR. Diagnosed: 1977&#x2013;85. End FU: 1996</td><td align="left">T, N, G, detection mode, HTyp</td><td align="left">TXN, age*N, Htyp*N, T*N*G</td><td align="left"/><td align="left">Overall survival was measured. Screening arrests disease progression. Tumour progression is more rapid in BC patients &lt;50&#xA0;yrs. OS of T1a(1&#x2013;5&#xA0;mm) vs. T1b(6&#x2013;10&#xA0;mm) NS.</td></tr><tr><td align="left">16</td><td align="left">Holmes 1999 [<xref ref-type="bibr" rid="CR85">85</xref>]</td><td align="left">1982</td><td align="left">13.1</td><td align="left">BMI &#x2265;30</td><td align="left">3rd  to 5th quintile of protein protein intake after diagnosis, N, T, G</td><td align="left">BMI, protein intake prior diagnosis, alcohol intake</td><td align="left">All cause mortality was measured. MV for BMI was corrected for age, diet interval, oral contraceptive use, hormone replacement therapy, MS, age at menarche, aget at birth and parity, smoking, T, G, N, ER, PR<break/> BMI &lt;21 and 1st quintile of protein intake were reference. Significant trend of higher mortality from lowest to highest quintiles of fibre, lutein and zeaxanthin, calcium and protein intake, with 13&#x2013;35% lowest mortality in the lowest quintile</td></tr><tr><td align="left">17</td><td align="left">Nomura 1999 [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left">1857 &lt;80&#xA0;yrs stage I-III</td><td align="left">12</td><td align="left">Second cancer and recurrence</td><td align="left">Age, ER, N, recurrence, second cancer</td><td align="left"/><td align="left">Overall survival was measured<break/>Recurrence is related to higher stage, younger age at diagnosis, Htyp, and therapy. Second cancer is related to younger age. Death related to recurrence and second cancer is increased 12 yrs after diagnosis.</td></tr><tr><td align="left">18</td><td align="left">Reed 1999 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">613 T1-2N0</td><td align="left">15.5</td><td align="left">Age &gt;50, T, G</td><td align="left">G, T, treatment</td><td align="left">UV: treatment, ER, PR, Her2, P53</td><td align="left">Overall survival was measured. Her2 was related to PR-, ER-negative, P53, G. P53 was related to PR-. Treatment was ovarian &amp; locoregional irradiation that had lower mortality rate</td></tr><tr><td align="left">19</td><td align="left">Aebi 2000 [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td align="left">3700 pre- &amp; perimenopausal</td><td align="left">12</td><td align="left">Age &lt;35&#xA0;vs. &#x2265;35</td><td align="left">N, T, G, age &lt;35*ER+</td><td align="left">Age, ER</td><td align="left">Overall survival was measured. Younger patients with ER+ who were not amenorrhoea had a significantly shorter survival</td></tr><tr><td align="left">20</td><td align="left">Ferrero 2000 [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left">297 N-</td><td align="left">11</td><td align="left">T, ER, P53</td><td align="left">T, ER</td><td align="left">Age, PR, G</td><td align="left">Breast cancer-specific survival was measured. P53 was related to grade, T, ER-negative. P53 was continuous variable</td></tr><tr><td align="left">21</td><td align="left">Kroman 2000 [<xref ref-type="bibr" rid="CR6">6</xref>]</td><td align="left">10,356 age &lt;50</td><td align="left">NR. Diagnosed: 1978&#x2013;96.</td><td align="left"/><td align="left">Age, T, N, G</td><td align="left">Period of treatment and surgery</td><td align="left">Relative survival was measured for excess mortality due to BC. When chemotherapy was given BC at young age does have worse prognosis</td></tr><tr><td align="left">22</td><td align="left">Ferrero-Pous 2000 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">488</td><td align="left">10</td><td align="left">ER, uPA, G, N, PR, P53 by Her2</td><td align="left">All patients: uPA, N, T, Her2, age<break/> In N&#x2212;: uPA, T<break/> In N+: N: uPA, T, age, Her2</td><td align="left"/><td align="left">Overall survival was measured. For patients who received chemotherapy uPA, T &amp; N determined OS. For patients who received hormonal therapy uPA, Her2 &amp; N determined OS</td></tr><tr><td align="left">23</td><td align="left">Kato 2001 [<xref ref-type="bibr" rid="CR44">44</xref>]<sup>a</sup></td><td align="left">377</td><td align="left">10</td><td align="left">T, N, G</td><td align="left">AMC, T, N, G</td><td align="left">Necrosis</td><td align="left">Overall survival was measured. AMC is a good prognostic factor for N- and T2-3 patients</td></tr><tr><td align="left">24</td><td align="left">Liu 2001 [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td align="left">791</td><td align="left">16.3</td><td align="left">T, N, G, ER, Her2, p53, MIB-1, MAI, AI</td><td align="left">All patients: N, T, G, ER, Her-2<break/> In N&#x2212;: G<break/> In N+: N, age, ER, Her2</td><td align="left">UV: age. MV All patients: AI, MI, MIB-1, ER, G MV in N- &amp; N+: AI, MI, ER, G.</td><td align="left">Breast cancer-specific mortality was measured. When patient FU was truncated at 5&#xA0;yrs, MI was prognostic factor for N+ and N-</td></tr><tr><td align="left">25</td><td align="left">Page 2001 [<xref ref-type="bibr" rid="CR115">115</xref>]</td><td align="left">311 no adjuvant therapy.</td><td align="left">11.6</td><td align="left">High risk group (ER- or T&#x2265;3cm) vs. low risk (ER+ and T &lt;2&#xA0;cm)</td><td align="left">T, risk group (high vs. low)</td><td align="left">G, MI</td><td align="left">Overall survival was measured. MI was only significant when FU was truncated at 5&#xA0;yrs. Grade was significant prognostic factor for short- and long-term survival</td></tr><tr><td align="left">26</td><td align="left">Frkovic-Grazio and Bracko 2001 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">270 T1N0M0</td><td align="left">12.5</td><td align="left">G, Tubular score, MI</td><td align="left">Tubular score and MI</td><td align="left"/><td align="left">Breast cancer-specific survival was measured. This study confirmed the use of Nottingham grading system in their cohort</td></tr><tr><td align="left">27</td><td align="left">D&#x2019;Eredita 2001 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">402</td><td align="left">&#x2265;16</td><td align="left">T, N, Htyp, G, LVI, NPI</td><td align="left">T, N, G</td><td align="left">UV: Age, MS, ER, type of surgery<break/> MV: LVI &amp; Htyp</td><td align="left">Overall survival was measured. NPI gives similar survival prognosis as T, N, G</td></tr><tr><td align="left">28</td><td align="left">Thomson 2001 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">23786</td><td align="left">At 10&#xA0;yrs about 50% patients were alive</td><td align="left">Age stratified by SES</td><td align="left">Intermediate vs. high SES group corrected for age, ER, N, T, stage</td><td align="left">Deprived vs. high SES group corrected for age, ER, N, T, stage</td><td align="left">Deprived women have more ER- tumours. ER distribution and treatment method accounted for 20% of disparities in survival</td></tr><tr><td align="left">29</td><td align="left">Vorgias 2001 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">269 stage II</td><td align="left">12</td><td align="left">NR</td><td align="left">T, N, age, ER/PR</td><td align="left">MS, therapy</td><td align="left">Overall survival was measured</td></tr><tr><td align="left">30</td><td align="left">Vincent-Salomon 2001 [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">685 T&#x2264;3&#xA0;cm</td><td align="left">10.8</td><td align="left">G, N, ER, necrosis</td><td align="left">N, necrosis, G</td><td align="left">UV: Vascular density, LVI, age, PR</td><td align="left">Overall survival was measured. Intratumoral vascular density was related to larger tumour size and higher grade</td></tr><tr><td align="left">31</td><td align="left">Eerola 2001 [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left">Familial BC: 359<break/>Sporadic BC: 59517</td><td align="left">NR<break/> Diagnosed: 1953&#x2013;1995 End FU: 1997</td><td align="left"/><td align="left">Stage, age, period of BC diagnosis, FU time (after 2 and 3&#xA0;yrs of diagnosis)</td><td align="left">BRCA1, BRCA2</td><td align="left">5-year relative survival was measured for excess mortality due to BC</td></tr><tr><td align="left">32</td><td align="left">Kitchen 2001 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">9520</td><td align="left">12</td><td align="left"/><td align="left">Tubular BC type vs. other type, by nodal status and chemotherapy</td><td align="left"/><td align="left">Overall survival was measured. Tubular BC type had better prognosis than other type. This type was more likely to have low G &amp; ER+</td></tr><tr><td align="left">33</td><td align="left">Kato 2002 [<xref ref-type="bibr" rid="CR50">50</xref>]<sup>a</sup></td><td align="left">422</td><td align="left">10</td><td align="left">P53, MI, necrosis, T, N, LVI</td><td align="left">MI, T, N</td><td align="left">UV: AI</td><td align="left">Overall survival was measured<break/>In MV P53 &amp; MI were independent prognostic factors for N-patients only. P53 was related to MI, AI, necrosis, G, T, N, ER/PR</td></tr><tr><td align="left">34</td><td align="left">Kato 2002 [<xref ref-type="bibr" rid="CR54">54</xref>]<sup>a</sup></td><td align="left">398</td><td align="left">10</td><td align="left">BVI, T, N, G, chemotherapy</td><td align="left">BVI, T, N, G, chemotherapy</td><td align="left">UV: necrosis</td><td align="left">Overall survival was measured</td></tr><tr><td align="left">35</td><td align="left">Costa 2002 [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">670</td><td align="left">11.4</td><td align="left">N, T, age, ER/PR</td><td align="left">N, T, age</td><td align="left">MS, ER/PR</td><td align="left">Breast cancer-specific survival was measured. After 5&#xA0;yrs of FU ER and PR were not independent prognostic factors</td></tr><tr><td align="left">36</td><td align="left">Menard 2002 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">1928</td><td align="left">Diagnosed in 1968&#x2013;69 and 1978&#x2013;79</td><td align="left">Her2, N, T, MS, lymphoid infiltration, PR-</td><td align="left">G, T, N, lymphoid infiltration</td><td align="left"/><td align="left">Overall survival was measured. HER-2 was related to large tumours, higher G, lymphoid infiltration, higher mitotic index, PR-</td></tr><tr><td align="left">37</td><td align="left">Van de Vijver 2002 [<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left">295 age &lt;53, stage I-II</td><td align="left">6.7</td><td align="left">Gene profile (Good vs. bad prognosis) for all patients, N+, N&#x2212;</td><td align="left">Gene profile, T, N, chemotherapy</td><td align="left">VI, G, age, hormonal therapy</td><td align="left">Overall survival was measured</td></tr><tr><td align="left">38</td><td align="left">Van&#x2019;t Veer 2002 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left">117 age &lt;55</td><td align="left">NR</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Better classification of patients with high risk of metastasis and in need of chemotherapy</td></tr><tr><td align="left">39</td><td align="left">Hatteville 2002 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">3180</td><td align="left">15.8</td><td align="left"/><td align="left">OS &lt;5&#xA0;year: N, G, recurrence or metastasis OS&#x2265;5&#xA0;yr: G and recurrence or metastasis</td><td align="left">Age, T</td><td align="left">If patient remains without recurrence or metastasis, effect of prognostic factors decreases over time. With metastases, this effect increases</td></tr><tr><td align="left">40</td><td align="left">Sotiriou 2003 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left">99</td><td align="left">6.1</td><td align="left">Gene profile (luminal 1&#x2013;3 vs. basal 1&#x2013;2 &amp; Her2 type)</td><td align="left"/><td align="left"/><td align="left">Luminal-like 1&#x2013;3 was predominantly ER+. Basal-like 1&#x2013;2 and Her2 was predominantly ER-</td></tr><tr><td align="left">41</td><td align="left">Dignam 2003 [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td align="left">3385 N&#x2212;, ER+</td><td align="left">13.8</td><td align="left"/><td align="left">BMI &lt;18.5 and BMI &#x2265;30 higher total mortality and other deaths.</td><td align="left">BMI on deaths after BC events.</td><td align="left">Total mortality, death after BC events and other deaths as well as recurrence rate and occurrence of a second cancer was were measured. MV was adjusted for treatment, age, MS, race, T, ER and PR. Reference group was BMI 18.5&#x2013;24.9.</td></tr><tr><td align="left">42</td><td align="left">Olivotto 2003 [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">620 stage IIIB-M1</td><td align="left">&gt;20</td><td align="left">Supraclavicular BC, Stage IIIB and M1</td><td align="left"/><td align="left"/><td align="left">Overall and breast cancer specific survival were measured. Patients with supraclavicular metastases had significantly better survival than patients with M1. Survival of these patients resembles that of BC stage IIB. (FU for living patients 20 yrs, for all patients 4.5&#xA0;yrs)</td></tr><tr><td align="left">43</td><td align="left">Weiss 2003 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">905 N+ Chemotherapy+</td><td align="left">22.6</td><td align="left">N+ (N1&#x2013;3 vs. N4&#x2013;9 vs. N &gt;10), also by treatment and follow-up time</td><td align="left">N, T, MS</td><td align="left">MV: NXT, MSXT, additional vincristine and prednison</td><td align="left">Overall survival was measured. N was related to T. MS was related to receptor status</td></tr><tr><td align="left">44</td><td align="left">Taylor 2003 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">54,228</td><td align="left">At 10&#xA0;yrs 65% patients were alive</td><td align="left">Period of diagnosis, stage by age, FU time by stage</td><td align="left"/><td align="left"/><td align="left">Relative survival was measured for excess mortality due to BC<break/>The longer the survival the better the prognosis. Improvement in relative survival for all patients and all stages since 1972</td></tr><tr><td align="left">45</td><td align="left">Dales 2004 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">905 aged 25&#x2013;81</td><td align="left">11.7</td><td align="left">In N- : CD105+ vessels. In all pts: CD31, Tie-2/Tek</td><td align="left">In all pts: G, CD105 vessels, ER<break/> In N&#x2212;: G, CD105 vessels, PR</td><td align="left">In all pts: T, Htyp, CD31, PR, age. In N&#x2212;: T, CD31 vessels, ER, age</td><td align="left">Overall survival was measured. MV: Tie-2/Tek showed significant role for predicting OS in all patients and N- patients</td></tr><tr><td align="left">46</td><td align="left">Brenner and Hakulinen 2004 [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">18,578 age &lt;50</td><td align="left">NR. Diagnosed: 1953&#x2013;1999.</td><td align="left">Period of diagnosis, stage, stage*period, time after diagnosis</td><td align="left"/><td align="left"/><td align="left">Improvement of prognosis for BC patients younger than 50 over the past decades. Relative survival remains lowered even 40 yrs after diagnosis</td></tr><tr><td align="left">47</td><td align="left">Robson 2004 [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td align="left">584 Ashkenazi Jewish</td><td align="left">116</td><td align="left">BRCA1, T, N, ER, age, chemotherapy</td><td align="left">BRCA1, T, N, Age</td><td align="left">Tamoksifen, BRCA2</td><td align="left">Breast cancer-specific survival was measured. No effect of BRCA on non-BC death. BRCA1 only predicted BC death in patients without chemotherapy</td></tr><tr><td align="left">48</td><td align="left">Chia 2004 [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">1187 LVI-, N-, Adjuvant systemic therapy-</td><td align="left">10.4</td><td align="left">T, G</td><td align="left">TXG</td><td align="left"/><td align="left">Overall and breast cancer specific survival were measured. Patients with higher grade and size have greater chance to die from other &amp; those with low risk disease greater chance of death from BC</td></tr><tr><td align="left">49</td><td align="left">Yoshimoto 2004 [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">15,416</td><td align="left">NR. Diagnosed 1946&#x2013;2001.</td><td align="left">Period of diagnosis</td><td align="left"/><td align="left"/><td align="left">Over the decades, there were less extensive surgery and lymph node examination, less radiotherapy, more chemo- and hormonal therapy</td></tr><tr><td align="left">50</td><td align="left">Houterman 2004 [<xref ref-type="bibr" rid="CR116">116</xref>]</td><td align="left">527 age &#x2265;40</td><td align="left">4.7</td><td align="left">Comorbidity, N, Therapy, age&#x2265;70, comorbidity*N</td><td align="left">In age &lt;70: comorbidity, N In age &#x2265;70: comorbidity, age</td><td align="left">In age &lt;70: therapy<break/> In pts age&#x2265;70: N, therapy</td><td align="left">Relative survival was measured for excess mortality due to BC<break/> Older patients with comorbidity were not treated differently but had a worse prognosis</td></tr><tr><td align="left">51</td><td align="left">Schoppmann 2004 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">374</td><td align="left">22.4</td><td align="left">LVI, G, N, Therapy</td><td align="left">LVI, G, N</td><td align="left">LMVD (Lymphatic Microvessel Density), T, Htyp, ER, age, MS</td><td align="left">Overall survival was measured. LVI is related to young premenopausal BC, lower G, N+</td></tr><tr><td align="left">52</td><td align="left">Warwick 2004 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">2299</td><td align="left">&gt;10</td><td align="left">G, N, T, Metastases</td><td align="left">G, N, T, Metastases</td><td align="left"/><td align="left">Breast cancer specific survival was measured. All studied factors predicted long-term survival, but their value decreased over time</td></tr><tr><td align="left">53</td><td align="left">Berclaz 2004 [<xref ref-type="bibr" rid="CR82">82</xref>]</td><td align="left">6792</td><td align="left">14</td><td align="left">BMI 25&#x2013;29, BMI &#x2265;30 lower overall survival</td><td align="left">BMI &#x2265;30</td><td align="left">BMI 25&#x2013;29</td><td align="left">Overall survival and also disease free survival were measured. Reference group was BMI &#x2264; 24.9. MV adjusted for ER, T, N, MS, treatment, chemotherapy, hormonal- in combination with chemotherapy</td></tr><tr><td align="left">54</td><td align="left">Dignam 2005 [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left">4077 N-, ER-</td><td align="left">NR</td><td align="left"/><td align="left">BMI &#x2265;35 and AA had higher overall mortality and non- BC death</td><td align="left">BMI and race on death after BC events</td><td align="left">Total mortality, death after BC events and other deaths as well as recurrence rate and occurrence of a second cancer were measured. MV was adjusted for treatment, age, MS, race, T, ER and PR<break/> Reference group was BMI &#x2264;24.9</td></tr><tr><td align="left">55</td><td align="left">Holmes 2005 [<xref ref-type="bibr" rid="CR87">87</xref>]</td><td align="left">2987</td><td align="left">96&#xA0;months</td><td align="left"/><td align="left">Physical activity after diagnosis (MET &#x2265;9) on BC and total mortality</td><td align="left"/><td align="left">Breast cancer and total mortality were measured. MV corrected for age, interval between diagnosis and physical activity assessment, smoking, BMI, MS, hormone therapy use, age at first birth, parity, energy intake, stage and treatment. MET: metabolic equivalent task hours per week. Patients with BMI &#x2265;25 and more physical activity before diagnosis there was a significant trend for less breast cancer death</td></tr><tr><td align="left">56</td><td align="left">Robsahm and Tretli 2005 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">5042</td><td align="left">NR. Diagnosed: 1964&#x2013;92. End FU: 1992</td><td align="left">NR</td><td align="left">Location of home, age at first child, physical activity at work</td><td align="left">MV corrected for: age, period of diagnosis, birth cohort, educational level</td><td align="left">Breast cancer-specific survival was measured. Incidence of BC increases with higher educational level, and case fatality decreases by increasing education level</td></tr><tr><td align="left">57</td><td align="left">Vu-Nishino 2005 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">1490 received breast- conserving treatment</td><td align="left">13.9</td><td align="left"/><td align="left"/><td align="left">Medullary BC vs. other BC type</td><td align="left">Overall survival was measured. Medullary BC type had better prognosis than other type. This type was more likely to have ER+, PR+ &amp; less BRCA1/2 mutation. Medullary type was only a prognostic factor for the first 5&#xA0;yrs</td></tr><tr><td align="left">58</td><td align="left">Galper 2005 [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">2102 stage I-II, 314 with local recurrence (LR)</td><td align="left">13.1</td><td align="left">NR</td><td align="left">No LR treatment, Invasive LR, time (yrs) to local recurrence, age at initial BC diagnosis</td><td align="left">T, detection method, number of nodes sampled, ER/PR, histological type, G, LVI, margins</td><td align="left">Measure of survival: distant failure, second malignancy, or death<break/> Patients with a longer time to recurrence have prolonged survival</td></tr><tr><td align="left">59</td><td align="left">Voogd 2005 [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">266 BC with LR</td><td align="left">11.2 after LR for living pts</td><td align="left">NR</td><td align="left">Location of LR, size of LR, skin involvement of LR, N+ for primary tumour</td><td align="left"/><td align="left">Overall survival was measured. Early detection of local recurrence may improve the treatment outcome</td></tr><tr><td align="left">60</td><td align="left">Louwman 2005 [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">8966</td><td align="left">Diagnosed 1995&#x2013;2001. End FU: 2004</td><td align="left">2 or more comorbidities, diabetes mellitus and previous cancer</td><td align="left">Previous cancer, CVD, DM, cerebrovascular disease, dementia, 2 or more comorbidities, stage, treatment (RT, ST, age)</td><td align="left"/><td align="left">Overall as well as relative survival was measured for excess mortality due to BC<break/> Primary treatment of BC patients with serious comorbidity was less extensive than treatment of those without comorbidity</td></tr><tr><td align="left">61</td><td align="left">Tammemagi 2005 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">906</td><td align="left">10</td><td align="left">Number of severe comorbidities, race, type of comorbidity</td><td align="left">All patients: 3 or more comorbidities adjusted for stage, age, ER, surgery, chemotherapy, radiotherapy</td><td align="left"/><td align="left">Overall survival was measured. AA had more diabetes and hypertension. After adjustment for these 2 comorbidities disparity disappeared</td></tr><tr><td align="left">62</td><td align="left">Meunier-Carpentier 2005 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">909/918 age: 25&#x2013;81</td><td align="left">11.3</td><td align="left">Tie2</td><td align="left">&#x2013;</td><td align="left">UV: VEGFR-2, VEGFR-2</td><td align="left">Overall survival was measured. VEGFR-1 and Tie2 were reported as independent prognostic factors corrected for T, G, Htyp, in all patients and N-</td></tr><tr><td align="left">63</td><td align="left">Tai 2005 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">6184 Inflammatory BC</td><td align="left">NR. Diagnosed 1973&#x2013;1995. End FU: 2000</td><td align="left">Period of diagnosis</td><td align="left"/><td align="left"/><td align="left">Breast cancer-specific survival was measured. Prognosis has improved over the decades due to more aggressive therapy</td></tr><tr><td align="left">64</td><td align="left">Louwman 2005 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left">492 T1&#x2013;2 N0</td><td align="left">&gt;10&#xA0;yrs</td><td align="left">MAI</td><td align="left">OS: age, T<break/> BCS: MAI</td><td align="left">OS: HTyp, therapy, period of diagnosis. BCS: therapy, period of diagnosis, age, T, Htyp</td><td align="left">Overall (OS) as well as relative survival (BCS) was measured for excess mortality due to BC<break/> Higher MAI was a significant prognostic factor for N&#x2212; and N+, but only during the first 10&#xA0;yrs of FU</td></tr><tr><td align="left">65</td><td align="left">Arrigada 2006 [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td align="left">2410 T &#x2264;7&#xA0;cm N1&#x2013;2</td><td align="left">19</td><td align="left">T, skin fixation, muscle fixation, G, N, age</td><td align="left">Total FU: T, N, G, age &lt;35, age&#x2265;55<break/> FU 0&#x2013;5&#xA0;yrs: T, N, G, age &#x2265;55<break/> FU 5&#x2013;10&#xA0;yrs: N, G, age &lt;35, age&#xA0;&#x2265;&#xA0;55<break/> FU 10&#x2013;15&#xA0;yrs: N &gt;10, age &gt;55. FU 15&#x2013;20yrs: age&#x2265;65</td><td align="left"/><td align="left">Overall survival was measured. Long-term effect of prognostic factors vanishing</td></tr><tr><td align="left">66</td><td align="left">Newman 2006 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">90,124. White American: 76,111. AA: 14,013</td><td align="left"/><td align="left"/><td align="left">Age, stage, SES</td><td align="left"/><td align="left">Meta-analysis. African American is an independent predictor of poor outcome for overall survival and breast cancer specific mortality</td></tr><tr><td align="left">67</td><td align="left">Menvielle 2006 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">407,435 women followed for BC death (N:1408)</td><td align="left">Women who died of BC in 1968&#x2013;96</td><td align="left">Level of education by period of diagnosis</td><td align="left"/><td align="left"/><td align="left">Breast cancer death among women with the highest education compared to women with the lowest education in 1968&#x2013;74 was 0.43; and in 1990&#x2013;96: 1.17 (NS)</td></tr><tr><td align="left">68</td><td align="left">Bouchardy 2006 [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">3920 age &lt;70</td><td align="left">NR. Diagnosed in 1980&#x2013;2000</td><td align="left">SES</td><td align="left">SES corrected for age, period of diagnosis, marital status, country of birth, Htyp, ER, detection method, stage, sector of care, therapy</td><td align="left"/><td align="left">Overall survival was measured. Lowest SES had less frequently screen-detected cancers, less stage I, less lobular BC, less BCT, less lymph node dissection</td></tr><tr><td align="left">69</td><td align="left">Siegelmann-Danieli 2006 [<xref ref-type="bibr" rid="CR117">117</xref>]</td><td align="left">992, age &#x2265;70</td><td align="left">6.9</td><td align="left">Being in wheelchair, renal insufficiency, dementia, CHF, cardiac arrhythmia, DM, IHD, osteoporosis, PVD, cerebrovascular disease, COPD, Parkinson&#x2019;s disease, valvular heart disease</td><td align="left">In stage 1A-2A: age, CHF, DM, PVD, stage, cardiac arrhythmia, Parkinson&#x2019;s disease, renal insufficiency<break/> In stage 2B-4: G, stage, N, wheelchair-bound, renal insufficiency, COPD, age, DM</td><td align="left">Systemic therapy</td><td align="left">Overall survival was measured. CHF: Cardiac Heart Failure. DM: Diabetes Mellitus. IHD: Ischemic Heart Disease. PVD: Peripheral Heart Disease. COPD: Chronic Obstructive Pulmonary Disease. Role of comorbidity varies by age</td></tr><tr><td align="left">70</td><td align="left">Pritchard 2006 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left">639 premenopausal N+</td><td align="left">10</td><td align="left">Her2 amplification</td><td align="left">Her2 corrected for age, N, ER, type of surgery</td><td align="left"/><td align="left">Overall survival was measured. Those with amplified Her2 have improved survival with CEF</td></tr><tr><td align="left">71</td><td align="left">Lee 2006 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">(A) Adjuvant therapy &#x2212; : 990. (B) Adjuvant treatment +: 1765</td><td align="left">Group A: 13<break/> Group B: 6.8.</td><td align="left">LVI</td><td align="left">Group A: T, G, LVI, Htyp<break/>Group B: T, G, LVI, chemotherapy, hormonal therapy</td><td align="left">B: ER, age, Htyp</td><td align="left">Breast cancer-specific survival was measured<break/>For patients without adjuvant treatment, role of G in survival was higher in the first 5&#xA0;yrs. Role of Htyp was not significant for the first 5&#xA0;yrs of FU</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>indicates the overlapping patients used by the same author to answer another research question; yrs: years; UV: Univariate analysis. MV: Multivariate analysis. MS: Menopausal Status; T: Tumour size; N: Nodal involvement; Htyp: Histological type; MI: Mitotic Index; G: Grade; PR: Progesterone Receptor status; ER: Oestrogen Receptor status; PCNA: proliferating cell nuclear antigen; mos: months; NR: Not Reported; AA: African American; age: is in year and indicate age at primary breast cancer unless otherwise state; NPI: Nottingham Prognostic Index; LVI: Lymphovascular Invasion; (Prognostic factor)*(Prognostic factor): interaction between two factors; BMI: Body Mass Index; AMC: Average Microvessel Count; MAI: Mitotic Activity Index; AI: Apoptosis Index; FU: Follow-up; SES: Socioeconomic Status; BVI: Blood vessel Invasion; LMVD: Lymphatic Microvessel Density; LR: local recurrence; CVD: Cardiovascular Disease; DM: Diabetes Mellitus; RT: radiotherapy; ST: Systemic therapy; VEGFR: Vascular Endothelial Growth Factor Receptor; OS: Overall survival; BCS: Breast Cancer Specific Survival; NS: not significant; CHF: Cardiac Heart Failure; IHD: Ischemic Heart Disease. PVD: Peripheral Heart Disease. COPD: Chronic Obstructive Pulmonary. CEF: cyclophosphamide, epirubicin and fluorouracil</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Selected prognostic factors for long-term overall mortality of breast cancer (BC) patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient groups based</th><th align="left">Hazard ratio (HR) for overall follow-up or survival probability (S) 10&#xA0;years after diagnosis</th><th align="left">Morphology based</th><th align="left">Hazard ratio (HR) for overall follow-up or survival probability (S) 10&#xA0;years after diagnosis</th><th align="left">Molecular based</th><th align="left">Hazard ratio (HR) for overall follow-up or survival probability (S) 10&#xA0;years after diagnosis</th></tr></thead><tbody><tr><td align="left">Age at diagnosis [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td align="left">HR:</td><td align="left">Lymph node status [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">HR:</td><td align="left">HER2[<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">HR:</td></tr><tr><td align="left">&#x2003; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&lt;35&#xA0;vs. 35&#x2013;44</td><td align="left">1.4 (<italic>P</italic>: 0.07)</td><td align="left">&#x2003; N&#x2265;1 vs. N0</td><td align="left">2.4 (1.9&#x2013;2.9)</td><td align="left">&#x2003; &gt;500 vs. &#x2264;500</td><td align="left">1.82 (1.1&#x2013;2.9)</td></tr><tr><td align="left">&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;45&#x2013;54 vs. 35&#x2013;44</td><td align="left">1.1 (ns)</td><td align="left">Metastases vs. N0</td><td align="left">22.73 (16.1&#x2013;32.2)</td><td align="left"/><td align="left">Only in node-positive</td></tr><tr><td align="left">&#x2003; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;55&#x2013;64 vs. 35&#x2013;44</td><td align="left">2.0 (<italic>P</italic>: 0.000)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;65&#x2013;75 vs. 35&#x2013;44</td><td align="left">2.5 (<italic>P</italic>: 0.000)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Period of diagnosis [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">Relative survival<sup>b</sup>:</td><td align="left">Tumour size (mm)[<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">HR:</td><td align="left">Cell proliferation index</td><td align="left">HR:</td></tr><tr><td align="left">&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;1972&#x2013;1976</td><td align="left">59%</td><td align="left">&#x2003; T10&#x2013;14 vs. T1&#x2013;9</td><td align="left">1.2 (0.8&#x2013;1.9)</td><td align="left">(MAI)</td><td align="left"/></tr><tr><td align="left">&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;1977&#x2013;1986</td><td align="left">64%</td><td align="left">&#x2003; T15&#x2013;19 vs. T1&#x2013;9</td><td align="left">1.7 (1.1&#x2013;2.6)</td><td align="left">&#x2003; &gt;10 vs. &#x2264;10 [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="left">1.02 (1.00&#x2013;1.03)</td></tr><tr><td align="left" rowspan="3">&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;1987&#x2013;1991</td><td align="left" rowspan="3">70%</td><td align="left">&#x2003; T20&#x2013;29 vs. T1&#x2013;9</td><td align="left">2.5 (1.6&#x2013;3.9)</td><td align="left"/><td align="left">Only in node-positive patients</td></tr><tr><td align="left">&#x2003; T30&#x2013;49 vs. T1&#x2013;9</td><td align="left">3.8 (2.4&#x2013;6.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x2003; T&#x2265;50 vs. T1&#x2013;9</td><td align="left">4.6 (2.9&#x2013;7.6)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Time after diagnosis [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">Relative survival:</td><td align="left">Tumour grade [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">HR:</td><td align="left">Gene expression profile [<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left">S:</td></tr><tr><td align="left">&#x2003;&#xA0;&#xA0;&#xA0;0 vs. 5 yrs after diagnosis</td><td align="left"/><td align="left">&#x2003; II vs. I</td><td align="left">2.5 (1.0&#x2013;6.1)</td><td align="left"/><td align="left">55% vs. 95%</td></tr><tr><td align="left">&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Regional BC</td><td align="left">79% vs. 84%</td><td align="left">&#x2003; III vs. I</td><td align="left">5.7(2.6&#x2013;12.4)</td><td align="left">&#x2003; Poor vs. good signature<sup>f</sup></td><td align="left"/></tr><tr><td align="left">&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Locally advanced BC</td><td align="left">53% vs. 68%</td><td align="left"/><td char="." align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Socioeconomic status [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td char="." align="left">HR:</td><td align="left">Tumour type[<xref ref-type="bibr" rid="CR34">34</xref>]</td><td char="." align="left">S:</td><td align="left">ER/PR status [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">HR:</td></tr><tr><td align="left">&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Intermediate vs. affluent</td><td char="." align="left">1.2 (1.0&#x2013;1.4)</td><td align="left">&#x2003; Poor vs. excellent <sup>d,e</sup></td><td char="." align="left">&lt;50% vs. &gt;80%</td><td align="left">&#x2003; Positive vs. negative</td><td align="left">0.38 (0.02&#x2013;1.06)</td></tr><tr><td align="left">&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deprived vs. affluent</td><td char="." align="left">1.2 (0.99&#x2013;1.53)</td><td align="left"/><td char="." align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Lifestyle</td><td char="." align="left">HR:</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Body Mass Index</td><td char="." align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x2003;&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&lt;21 vs. 29+ kg/m<sup>2</sup></td><td char="." align="left">1.4 (0.97&#x2013;2.00) [<xref ref-type="bibr" rid="CR85">85</xref>] <sup>c</sup></td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Physical activity</td><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x2003;&#x2003;&#x2003;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&lt;&#xA0;3 vs. 23.9 MET-h/wk<sup><italic>a</italic></sup></td><td align="left">0.56 (0.4&#x2013;0.8) [<xref ref-type="bibr" rid="CR87">87</xref>]</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>HR: Hazard ratio calculated within multivariate analysis of breast cancer patients followed for a median/mean of 10&#xA0;years or longer <sup>a</sup> Metabolic equivalent task hours per week; <sup>b</sup> Estimates taken from graph; <sup>c</sup> Higher alcohol intake no significant effect on mortality. Significant trend of higher mortality for lowest compared to highest quintiles of fibre, lutein and zeaxanthin, calcium &amp; protein intake; <sup>d</sup> Becomes larger as numbers of involved lymph nodes increases [<xref ref-type="bibr" rid="CR8">8</xref>]; <sup>e</sup> Excellent prognosis: tubular, invasive cribriform, mucinous, tubulolobular. Poor prognosis: mixed lobular, solid lobular, ductal and mixed ductal lobular; <sup>f</sup> unadjusted estimates</p></table-wrap-foot></table-wrap></p>
      <p>Healthier lifestyle generally increases long-term survival. Modifiable risk factors (such as alcohol consumption and obesity) not only affect incidence but also tumour&#x2019; clinical behaviour and thus survival.</p>
      <p>Although a lot is known about the prognosis for BC patients, effect of traditional prognostic factors appears to attenuate over time, leaving room for studies on the role of other and newer factors for long-term survival.</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parkin</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Bray</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferlay</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global cancer statistics, 2002</article-title>
          <source>CA Cancer J Clin</source>
          <year>2005</year>
          <volume>55</volume>
          <fpage>74</fpage>
          <lpage>108</lpage>
        </citation>
        <citation citation-type="display-unstructured">Parkin DM, Bray F, Ferlay J et&#xA0;al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74&#x2013;108 <pub-id pub-id-type="pmid">15761078</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sant</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aareleid</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Berrino</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EUROCARE-3: survival of cancer patients diagnosed 1990&#x2013;94-results and commentary</article-title>
          <source>Ann Oncol</source>
          <year>2003</year>
          <volume>14</volume>
          <issue>Suppl 5</issue>
          <fpage>v61</fpage>
          <lpage>118</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sant M, Aareleid T, Berrino F et&#xA0;al (2003) EUROCARE-3: survival of cancer patients diagnosed 1990&#x2013;94-results and commentary. Ann Oncol 14(Suppl 5):v61&#x2013;118 <pub-id pub-id-type="pmid">14684501</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Botha</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bray</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sankila</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Breast cancer incidence and mortality trends in 16 European countries</article-title>
          <source>Eur J Cancer</source>
          <year>2003</year>
          <volume>39</volume>
          <fpage>1718</fpage>
          <lpage>1729</lpage>
        </citation>
        <citation citation-type="display-unstructured">Botha JL, Bray F, Sankila R et&#xA0;al (2003) Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39:1718&#x2013;1729 <pub-id pub-id-type="pmid">12888367</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="other">ACS: Cancer facts and figures 2005. Atlanta, 2005</citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="other">Janssen-Heijnen MLG, Louwman WJ, van de Poll-Franse LV et&#xA0;al (2005) Van meten naar weten. 50 jaar kankerregistratie. Integraal Kankercentrum Zuid (IKZ), Eindhoven, 104&#xA0;pp</citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kroman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Wohlfahrt</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Factors influencing the effect of age on prognosis in breast cancer: population based study</article-title>
          <source>BMJ</source>
          <year>2000</year>
          <volume>320</volume>
          <fpage>474</fpage>
          <lpage>478</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kroman N, Jensen MB, Wohlfahrt J et&#xA0;al (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474&#x2013;478 <pub-id pub-id-type="pmid">10678859</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aebi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gelber</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Castiglione-Gertsch</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer</article-title>
          <source>Lancet</source>
          <year>2000</year>
          <volume>355</volume>
          <fpage>1869</fpage>
          <lpage>1874</lpage>
        </citation>
        <citation citation-type="display-unstructured">Aebi S, Gelber S, Castiglione-Gertsch M et&#xA0;al (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869&#x2013;1874 <pub-id pub-id-type="pmid">10866443</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arriagada</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Dunant</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period</article-title>
          <source>Cancer</source>
          <year>2006</year>
          <volume>106</volume>
          <fpage>743</fpage>
          <lpage>750</lpage>
        </citation>
        <citation citation-type="display-unstructured">Arriagada R, Le MG, Dunant A et&#xA0;al (2006) Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer 106:743&#x2013;750 <pub-id pub-id-type="pmid">16411216</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tan-Chiu</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06</article-title>
          <source>Cancer</source>
          <year>2001</year>
          <volume>91</volume>
          <fpage>1679</fpage>
          <lpage>1687</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fisher ER, Anderson S, Tan-Chiu E et&#xA0;al (2001) Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 91:1679&#x2013;1687 <pub-id pub-id-type="pmid">11309768</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietilainen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lipponen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Aaltomaa</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of p53 protein has no independent prognostic value in breast cancer</article-title>
          <source>J Pathol</source>
          <year>1995</year>
          <volume>177</volume>
          <fpage>225</fpage>
          <lpage>232</lpage>
        </citation>
        <citation citation-type="display-unstructured">Pietilainen T, Lipponen P, Aaltomaa S et&#xA0;al (1995) Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177:225&#x2013;232 <pub-id pub-id-type="pmid">8551383</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kollias</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Elston</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>IO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early-onset breast cancer&#x2014;histopathological and prognostic considerations</article-title>
          <source>Br J Cancer</source>
          <year>1997</year>
          <volume>75</volume>
          <fpage>1318</fpage>
          <lpage>1323</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kollias J, Elston CW, Ellis IO et&#xA0;al (1997) Early-onset breast cancer&#x2014;histopathological and prognostic considerations. Br J Cancer 75:1318&#x2013;1323 <pub-id pub-id-type="pmid">9155052</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>West</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Satariano</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Ragland</surname>
              <given-names>DR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comorbidity and breast cancer survival: a comparison between black and white women</article-title>
          <source>Ann Epidemiol</source>
          <year>1996</year>
          <volume>6</volume>
          <fpage>413</fpage>
          <lpage>419</lpage>
        </citation>
        <citation citation-type="display-unstructured">West DW, Satariano WA, Ragland DR et&#xA0;al (1996) Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 6:413&#x2013;419 <pub-id pub-id-type="pmid">8915472</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Louwman</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Janssen-Heijnen</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Houterman</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study</article-title>
          <source>Eur J Cancer</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>779</fpage>
          <lpage>785</lpage>
        </citation>
        <citation citation-type="display-unstructured">Louwman WJ, Janssen-Heijnen ML, Houterman S et&#xA0;al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779&#x2013;785 <pub-id pub-id-type="pmid">15763655</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tammemagi</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Nerenz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Neslund-Dudas</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comorbidity and survival disparities among black and white patients with breast cancer</article-title>
          <source>JAMA</source>
          <year>2005</year>
          <volume>294</volume>
          <fpage>1765</fpage>
          <lpage>1772</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tammemagi CM, Nerenz D, Neslund-Dudas C et&#xA0;al (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294:1765&#x2013;1772 <pub-id pub-id-type="pmid">16219879</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hakulinen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Are patients diagnosed with breast cancer before age 50&#xA0;years ever cured</article-title>
          <source>J Clin Oncol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>432</fpage>
          <lpage>438</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brenner H, Hakulinen T (2004) Are patients diagnosed with breast cancer before age 50&#xA0;years ever cured? J Clin Oncol 22:432&#x2013;438 <pub-id pub-id-type="pmid">14691121</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Boyages</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival of women with breast cancer in New South Wales</article-title>
          <source>Eur J Cancer</source>
          <year>2003</year>
          <volume>39</volume>
          <fpage>215</fpage>
          <lpage>222</lpage>
        </citation>
        <citation citation-type="display-unstructured">Taylor R, Davis P, Boyages J (2003) Long-term survival of women with breast cancer in New South Wales. Eur J Cancer 39:215&#x2013;222 <pub-id pub-id-type="pmid">12509954</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Balsari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Casalini</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors</article-title>
          <source>Clin Cancer Res</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>520</fpage>
          <lpage>525</lpage>
        </citation>
        <citation citation-type="display-unstructured">Menard S, Balsari A, Casalini P et&#xA0;al (2002) HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8:520&#x2013;525 <pub-id pub-id-type="pmid">11839672</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshimoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hori</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improvement in the prognosis of Japanese breast cancer patients from 1946 to 2001&#x2013;an institutional review</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2004</year>
          <volume>34</volume>
          <fpage>457</fpage>
          <lpage>462</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yoshimoto M, Tada K, Hori H et&#xA0;al (2004) Improvement in the prognosis of Japanese breast cancer patients from 1946 to 2001&#x2013;an institutional review. Jpn J Clin Oncol 34:457&#x2013;462 <pub-id pub-id-type="pmid">15371463</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nystrom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Andersson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bjurstam</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term effects of mammography screening: updated overview of the Swedish randomised trials</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <fpage>909</fpage>
          <lpage>919</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nystrom L, Andersson I, Bjurstam N et&#xA0;al (2002) Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359:909&#x2013;919 <pub-id pub-id-type="pmid">11918907</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Otto</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Fracheboud</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Looman</surname>
              <given-names>CW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <fpage>1411</fpage>
          <lpage>1417</lpage>
        </citation>
        <citation citation-type="display-unstructured">Otto SJ, Fracheboud J, Looman CW et&#xA0;al (2003) Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361:1411&#x2013;1417 <pub-id pub-id-type="pmid">12727393</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatteville</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mahe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Prediction of the long-term survival in breast cancer patients according to the present oncological status</article-title>
          <source>Stat Med</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>2345</fpage>
          <lpage>2354</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hatteville L, Mahe C, Hill C (2002) Prediction of the long-term survival in breast cancer patients according to the present oncological status. Stat Med 21:2345&#x2013;2354 <pub-id pub-id-type="pmid">12210619</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gefeller</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hakulinen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Period analysis for &#x2019;up-to-date&#x2019; cancer survival data: theory, empirical evaluation, computational realisation and applications</article-title>
          <source>Eur J Cancer</source>
          <year>2004</year>
          <volume>40</volume>
          <fpage>326</fpage>
          <lpage>335</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for &#x2019;up-to-date&#x2019; cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326&#x2013;335 <pub-id pub-id-type="pmid">14746849</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hooning</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Aleman</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Rosmalen</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2006</year>
          <volume>64</volume>
          <fpage>1081</fpage>
          <lpage>1091</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hooning MJ, Aleman BM, van Rosmalen AJ et&#xA0;al (2006) Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 64:1081&#x2013;1091 <pub-id pub-id-type="pmid">16446057</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menvielle</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Leclerc</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chastang</surname>
              <given-names>JF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Social inequalities in breast cancer mortality among French women: disappearing educational disparities from 1968 to 1996</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>94</volume>
          <fpage>152</fpage>
          <lpage>155</lpage>
        </citation>
        <citation citation-type="display-unstructured">Menvielle G, Leclerc A, Chastang JF et&#xA0;al (2006) Social inequalities in breast cancer mortality among French women: disappearing educational disparities from 1968 to 1996. Br J Cancer 94:152&#x2013;155 <pub-id pub-id-type="pmid">16404368</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouchardy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Verkooijen</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Fioretta</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Social class is an important and independent prognostic factor of breast cancer mortality</article-title>
          <source>Int J Cancer</source>
          <year>2006</year>
          <volume>119</volume>
          <issue>5</issue>
          <fpage>1145</fpage>
          <lpage>1151</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bouchardy C, Verkooijen HM, Fioretta G (2006) Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer 119(5):1145&#x2013;1151 <pub-id pub-id-type="pmid">16557599</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomson</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Hole</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Twelves</surname>
              <given-names>CJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival</article-title>
          <source>J Epidemiol Community Health</source>
          <year>2001</year>
          <volume>55</volume>
          <fpage>308</fpage>
          <lpage>315</lpage>
        </citation>
        <citation citation-type="display-unstructured">Thomson CS, Hole DJ, Twelves CJ et&#xA0;al (2001) Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 55:308&#x2013;315 <pub-id pub-id-type="pmid">11297648</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robsahm</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Tretli</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Weak associations between sociodemographic factors and breast cancer: possible effects of early detection</article-title>
          <source>Eur J Cancer Prev</source>
          <year>2005</year>
          <volume>14</volume>
          <fpage>7</fpage>
          <lpage>12</lpage>
        </citation>
        <citation citation-type="display-unstructured">Robsahm TE, Tretli S (2005) Weak associations between sociodemographic factors and breast cancer: possible effects of early detection. Eur J Cancer Prev 14:7&#x2013;12 <pub-id pub-id-type="pmid">15677890</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wojcik</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Spinks</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Optenberg</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Breast carcinoma survival analysis for African American and white women in an equal-access health care system</article-title>
          <source>Cancer</source>
          <year>1998</year>
          <volume>82</volume>
          <fpage>1310</fpage>
          <lpage>1318</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wojcik BE, Spinks MK, Optenberg SA (1998) Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer 82:1310&#x2013;1218 <pub-id pub-id-type="pmid">9529023</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Griffith</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Jatoi</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>1342</fpage>
          <lpage>1349</lpage>
        </citation>
        <citation citation-type="display-unstructured">Newman LA, Griffith KA, Jatoi I et&#xA0;al (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24:1342&#x2013;1349 <pub-id pub-id-type="pmid">16549828</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vorgias</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Koukouras</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Paleogianni</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic significance of factors affecting disease free interval and overall survival for Stage II breast cancer in Greece. A multivariate cohort study</article-title>
          <source>Eur J Obstet Gynecol Reprod Biol</source>
          <year>2001</year>
          <volume>95</volume>
          <fpage>100</fpage>
          <lpage>104</lpage>
        </citation>
        <citation citation-type="display-unstructured">Vorgias G, Koukouras D, Paleogianni V et&#xA0;al (2001) Prognostic significance of factors affecting disease free interval and overall survival for Stage II breast cancer in Greece. A multivariate cohort study. Eur J Obstet Gynecol Reprod Biol 95:100&#x2013;104 <pub-id pub-id-type="pmid">11267729</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warwick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tabar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vitak</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Time-dependent effects on survival in breast carcinoma: results of 20&#xA0;years of follow-up from the Swedish Two-County Study</article-title>
          <source>Cancer</source>
          <year>2004</year>
          <volume>100</volume>
          <fpage>1331</fpage>
          <lpage>1336</lpage>
        </citation>
        <citation citation-type="display-unstructured">Warwick J, Tabar L, Vitak B et&#xA0;al (2004) Time-dependent effects on survival in breast carcinoma: results of 20&#xA0;years of follow-up from the Swedish Two-County Study. Cancer 100:1331&#x2013;1336 <pub-id pub-id-type="pmid">15042664</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Woolf</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Demakos</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Natural history of more than 20&#xA0;years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>1825</fpage>
          <lpage>1835</lpage>
        </citation>
        <citation citation-type="display-unstructured">Weiss RB, Woolf SH, Demakos E et&#xA0;al (2003) Natural history of more than 20&#xA0;years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 21:1825&#x2013;1835 <pub-id pub-id-type="pmid">12721260</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chia</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Speers</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Bryce</surname>
              <given-names>CJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies</article-title>
          <source>J Clin Oncol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>1630</fpage>
          <lpage>1637</lpage>
        </citation>
        <citation citation-type="display-unstructured">Chia SK, Speers CH, Bryce CJ et&#xA0;al (2004) Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22:1630&#x2013;1637 <pub-id pub-id-type="pmid">15117985</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galea</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Blamey</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Elston</surname>
              <given-names>CE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Nottingham Prognostic Index in primary breast cancer</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>1992</year>
          <volume>22</volume>
          <fpage>207</fpage>
          <lpage>219</lpage>
        </citation>
        <citation citation-type="display-unstructured">Galea MH, Blamey RW, Elston CE et&#xA0;al (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207&#x2013;219 <pub-id pub-id-type="pmid">1391987</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitchen</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy</article-title>
          <source>ANZ J Surg</source>
          <year>2001</year>
          <volume>71</volume>
          <fpage>27</fpage>
          <lpage>31</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kitchen PR, Smith TH, Henderson MA et&#xA0;al (2001) Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ J Surg 71:27&#x2013;31 <pub-id pub-id-type="pmid">11167594</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Northridge</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Rhoads</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Wartenberg</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The importance of histologic type on breast cancer survival</article-title>
          <source>J Clin Epidemiol</source>
          <year>1997</year>
          <volume>50</volume>
          <fpage>283</fpage>
          <lpage>290</lpage>
        </citation>
        <citation citation-type="display-unstructured">Northridge ME, Rhoads GG, Wartenberg D et&#xA0;al (1997) The importance of histologic type on breast cancer survival. J Clin Epidemiol 50:283&#x2013;290 <pub-id pub-id-type="pmid">9120527</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reed</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hannisdal</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Boehler</surname>
              <given-names>PJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14&#x2013;30&#xA0;years</article-title>
          <source>Cancer</source>
          <year>2000</year>
          <volume>88</volume>
          <fpage>804</fpage>
          <lpage>813</lpage>
        </citation>
        <citation citation-type="display-unstructured">Reed W, Hannisdal E, Boehler PJ et&#xA0;al (2000) The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14&#x2013;30&#xA0;years. Cancer 88:804&#x2013;813 <pub-id pub-id-type="pmid">10679650</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vu-Nishino</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tavassoli</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Ahrens</surname>
              <given-names>WA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT)</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2005</year>
          <volume>62</volume>
          <fpage>1040</fpage>
          <lpage>1047</lpage>
        </citation>
        <citation citation-type="display-unstructured">Vu-Nishino H, Tavassoli FA, Ahrens WA et&#xA0;al (2005) Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys 62:1040&#x2013;1047 <pub-id pub-id-type="pmid">15990007</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gamel</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Feuer</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma</article-title>
          <source>Cancer</source>
          <year>1996</year>
          <volume>77</volume>
          <fpage>1459</fpage>
          <lpage>1464</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gamel JW, Meyer JS, Feuer E et&#xA0;al (1996) The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer 77:1459&#x2013;1464 <pub-id pub-id-type="pmid">8608529</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tai</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Shiels</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Short- and long-term cause-specific survival of patients with inflammatory breast cancer</article-title>
          <source>BMC Cancer</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>137</fpage>
        </citation>
        <citation citation-type="display-unstructured">Tai P, Yu E, Shiels R et&#xA0;al (2005) Short- and long-term cause-specific survival of patients with inflammatory breast cancer. BMC Cancer 5:137 <pub-id pub-id-type="pmid">16242046</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Lippman</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Diseases of the breast</source>
          <year>2004</year>
          <edition>3</edition>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
        </citation>
        <citation citation-type="display-unstructured">Harris JR, Lippman ME, Morrow M et&#xA0;al (2004) Diseases of the breast 3rd edn. Philadelphia, Lippincott Williams &amp; Wilkins </citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilchrist</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Kalish</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gould</surname>
              <given-names>VE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>1985</year>
          <volume>5</volume>
          <fpage>3</fpage>
          <lpage>10</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gilchrist KW, Kalish L, Gould VE et&#xA0;al (1985) Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study. Breast Cancer Res Treat 5:3&#x2013;10 <pub-id pub-id-type="pmid">3978246</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vincent-Salomon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zafrani</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases</article-title>
          <source>Cancer</source>
          <year>2001</year>
          <volume>92</volume>
          <fpage>249</fpage>
          <lpage>256</lpage>
        </citation>
        <citation citation-type="display-unstructured">Vincent-Salomon A, Carton M, Zafrani B et&#xA0;al (2001) Long term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases. Cancer 92:249&#x2013;256 <pub-id pub-id-type="pmid">11466676</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kameoka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2001</year>
          <volume>70</volume>
          <fpage>65</fpage>
          <lpage>74</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kato T, Kameoka S, Kimura T et&#xA0;al (2001) Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer. Breast Cancer Res Treat 70:65&#x2013;74 <pub-id pub-id-type="pmid">11767005</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Duffy</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Vitak</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The natural history of breast carcinoma: what have we learned from screening</article-title>
          <source>Cancer</source>
          <year>1999</year>
          <volume>86</volume>
          <fpage>449</fpage>
          <lpage>462</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tabar L, Duffy SW, Vitak B et&#xA0;al (1999) The natural history of breast carcinoma: what have we learned from screening? Cancer 86:449&#x2013;462 <pub-id pub-id-type="pmid">10430253</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kollias</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Elston</surname>
              <given-names>CW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prognosis of small primary breast cancers</article-title>
          <source>Eur J Cancer</source>
          <year>1999</year>
          <volume>35</volume>
          <fpage>908</fpage>
          <lpage>912</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kollias J, Murphy CA, Elston CW et&#xA0;al (1999) The prognosis of small primary breast cancers. Eur J Cancer 35:908&#x2013;912 <pub-id pub-id-type="pmid">10533470</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pinder</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>IO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy</article-title>
          <source>Cancer</source>
          <year>1998</year>
          <volume>83</volume>
          <fpage>1529</fpage>
          <lpage>1539</lpage>
        </citation>
        <citation citation-type="display-unstructured">Pinder SE, Murray S, Ellis IO et&#xA0;al (1998) The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 83:1529&#x2013;1539 <pub-id pub-id-type="pmid">9781946</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frkovic-Grazio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bracko</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma</article-title>
          <source>J Clin Pathol</source>
          <year>2002</year>
          <volume>55</volume>
          <fpage>88</fpage>
          <lpage>92</lpage>
        </citation>
        <citation citation-type="display-unstructured">Frkovic-Grazio S, Bracko M (2002) Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol 55:88&#x2013;92 <pub-id pub-id-type="pmid">11865000</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#x2019;Eredita</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giardina</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Martellotta</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution</article-title>
          <source>Eur J Cancer</source>
          <year>2001</year>
          <volume>37</volume>
          <fpage>591</fpage>
          <lpage>596</lpage>
        </citation>
        <citation citation-type="display-unstructured">D&#x2019;Eredita G, Giardina C, Martellotta M et&#xA0;al (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591&#x2013;596 <pub-id pub-id-type="pmid">11290434</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kameoka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer</article-title>
          <source>Anticancer Res</source>
          <year>2002</year>
          <volume>22</volume>
          <fpage>1105</fpage>
          <lpage>1112</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kato T, Kameoka S, Kimura T et&#xA0;al (2002) p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res 22:1105&#x2013;1112 <pub-id pub-id-type="pmid">12168908</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldhirsch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Glick</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Gelber</surname>
              <given-names>RD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005</article-title>
          <source>Ann Oncol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>1569</fpage>
          <lpage>1583</lpage>
        </citation>
        <citation citation-type="display-unstructured">Goldhirsch A, Glick JH, Gelber RD et&#xA0;al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569&#x2013;1583 <pub-id pub-id-type="pmid">16148022</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Pinder</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Macmillan</surname>
              <given-names>RD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma</article-title>
          <source>Eur J Cancer</source>
          <year>2006</year>
          <volume>42</volume>
          <fpage>357</fpage>
          <lpage>362</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lee AH, Pinder SE, Macmillan RD et&#xA0;al (2006) Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 42:357&#x2013;362 <pub-id pub-id-type="pmid">16377180</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schoppmann</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Bayer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Aumayr</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer</article-title>
          <source>Ann Surg</source>
          <year>2004</year>
          <volume>240</volume>
          <fpage>306</fpage>
          <lpage>312</lpage>
        </citation>
        <citation citation-type="display-unstructured">Schoppmann SF, Bayer G, Aumayr K et&#xA0;al (2004) Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240:306&#x2013;312 <pub-id pub-id-type="pmid">15273556</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kameoka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Blood vessel invasion as a predictor of long-term survival for Japanese patients with breast cancer</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2002</year>
          <volume>73</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kato T, Kameoka S, Kimura T et&#xA0;al (2002) Blood vessel invasion as a predictor of long-term survival for Japanese patients with breast cancer. Breast Cancer Res Treat 73:1&#x2013;12 <pub-id pub-id-type="pmid">12083626</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meunier-Carpentier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dales</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Djemli</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma</article-title>
          <source>Int J Oncol</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>977</fpage>
          <lpage>984</lpage>
        </citation>
        <citation citation-type="display-unstructured">Meunier-Carpentier S, Dales JP, Djemli A et&#xA0;al (2005) Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 26:977&#x2013;984 <pub-id pub-id-type="pmid">15753992</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dales</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carpentier</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression</article-title>
          <source>Hum Pathol</source>
          <year>2004</year>
          <volume>35</volume>
          <fpage>176</fpage>
          <lpage>183</lpage>
        </citation>
        <citation citation-type="display-unstructured">. Dales JP, Garcia S, Carpentier S et&#xA0;al (2004) Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 35:176&#x2013;183 <pub-id pub-id-type="pmid">14991534</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olivotto</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Chua</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>SJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>851</fpage>
          <lpage>854</lpage>
        </citation>
        <citation citation-type="display-unstructured">Olivotto IA, Chua B, Allan SJ et&#xA0;al (2003) Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol 21:851&#x2013;854 <pub-id pub-id-type="pmid">12610184</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nomura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsutsui</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic impact of second cancer on the survival of early breast cancer patients</article-title>
          <source>Int J Oncol</source>
          <year>1999</year>
          <volume>14</volume>
          <fpage>1103</fpage>
          <lpage>1109</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nomura Y, Tsutsui S, Murakami S et&#xA0;al (1999) Prognostic impact of second cancer on the survival of early breast cancer patients. Int J Oncol 14:1103&#x2013;1109 <pub-id pub-id-type="pmid">10339665</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raymond</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hogue</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Multiple primary tumours in women following breast cancer, 1973&#x2013;2000</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>94</volume>
          <fpage>1745</fpage>
          <lpage>1750</lpage>
        </citation>
        <citation citation-type="display-unstructured">Raymond JS, Hogue CJ (2006) Multiple primary tumours in women following breast cancer, 1973&#x2013;2000. Br J Cancer 94:1745&#x2013;1750 <pub-id pub-id-type="pmid">16721370</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kollias</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>IO</given-names>
            </name>
            <name>
              <surname>Elston</surname>
              <given-names>CW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic significance of synchronous and metachronous bilateral breast cancer</article-title>
          <source>World J Surg</source>
          <year>2001</year>
          <volume>25</volume>
          <fpage>1117</fpage>
          <lpage>1124</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kollias J, Ellis IO, Elston CW et&#xA0;al (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25:1117&#x2013;1124 <pub-id pub-id-type="pmid">11571945</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wapnir</surname>
              <given-names>IL</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Mamounas</surname>
              <given-names>EP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>2028</fpage>
          <lpage>2037</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wapnir IL, Anderson SJ, Mamounas EP et&#xA0;al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028&#x2013;2037 <pub-id pub-id-type="pmid">16648502</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Voogd</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Oost</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Rutgers</surname>
              <given-names>EJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer</article-title>
          <source>Eur J Cancer</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>2637</fpage>
          <lpage>2644</lpage>
        </citation>
        <citation citation-type="display-unstructured">Voogd AC, van Oost FJ, Rutgers EJ et&#xA0;al (2005) Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 41:2637&#x2013;2344 <pub-id pub-id-type="pmid">16115758</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blood</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gelman</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2005</year>
          <volume>61</volume>
          <fpage>348</fpage>
          <lpage>357</lpage>
        </citation>
        <citation citation-type="display-unstructured">Galper S, Blood E, Gelman R et&#xA0;al (2005) Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys 61:348&#x2013;357 <pub-id pub-id-type="pmid">15667952</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Habel</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Shak</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>MK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients</article-title>
          <source>Breast Cancer Res</source>
          <year>2006</year>
          <volume>8</volume>
          <fpage>R25</fpage>
        </citation>
        <citation citation-type="display-unstructured">Habel LA, Shak S, Jacobs MK et&#xA0;al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25 <pub-id pub-id-type="pmid">16737553</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obedian</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Haffty</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy</article-title>
          <source>J Clin Oncol</source>
          <year>2000</year>
          <volume>18</volume>
          <fpage>2406</fpage>
          <lpage>2412</lpage>
        </citation>
        <citation citation-type="display-unstructured">Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18:2406&#x2013;2412 <pub-id pub-id-type="pmid">10856100</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="other">Early Breast Cancer Trialists&#x2019; Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687&#x2013;1717 </citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costa</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klinga</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer&#x2014;results of the analysis of 670 patients with 11&#xA0;years of follow-up</article-title>
          <source>Eur J Cancer</source>
          <year>2002</year>
          <volume>38</volume>
          <fpage>1329</fpage>
          <lpage>1334</lpage>
        </citation>
        <citation citation-type="display-unstructured">Costa SD, Lange S, Klinga K et&#xA0;al (2002) Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer&#x2014;results of the analysis of 670 patients with 11&#xA0;years of follow-up. Eur J Cancer 38:1329&#x2013;1334 <pub-id pub-id-type="pmid">12091062</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pritchard</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>O&#x2019;Malley</surname>
              <given-names>FP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HER2 and responsiveness of breast cancer to adjuvant chemotherapy</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>354</volume>
          <fpage>2103</fpage>
          <lpage>2111</lpage>
        </citation>
        <citation citation-type="display-unstructured">Pritchard KI, Shepherd LE, O&#x2019;Malley FP et&#xA0;al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103&#x2013;2111 <pub-id pub-id-type="pmid">16707747</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrero-Pous</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hacene</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bouche</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis</article-title>
          <source>Clin Cancer Res</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>4745</fpage>
          <lpage>4754</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ferrero-Pous M, Hacene K, Bouchet C et&#xA0;al (2000) Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 6:4745&#x2013;4754 <pub-id pub-id-type="pmid">11156229</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haerslev</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Zedeler</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein in breast carcinoma with correlations to histopathological parameters and prognosis</article-title>
          <source>Oncol Rep</source>
          <year>1995</year>
          <volume>2</volume>
          <fpage>99</fpage>
          <lpage>105</lpage>
        </citation>
        <citation citation-type="display-unstructured">Haerslev T, Jacobsen GK, Zedeler K (1995) Proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein in breast carcinoma with correlations to histopathological parameters and prognosis. Oncol Rep 2:99&#x2013;105 </citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Louwman</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Beek</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Schapers</surname>
              <given-names>RF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to mitotic activity index: a population-based study</article-title>
          <source>Int J Cancer</source>
          <year>2005</year>
          <volume>118</volume>
          <issue>9</issue>
          <fpage>2310</fpage>
          <lpage>2314</lpage>
        </citation>
        <citation citation-type="display-unstructured">Louwman WJ, van Beek MW, Schapers RF et&#xA0;al (2005) Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to mitotic activity index: a population-based study. Int J Cancer 118(9):2310&#x2013;2314 <pub-id pub-id-type="pmid">16331599</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veer</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vijver</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>415</volume>
          <fpage>530</fpage>
          <lpage>536</lpage>
        </citation>
        <citation citation-type="display-unstructured">van &#x2019;t Veer LJ, Dai H, van de Vijver MJ et&#xA0;al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530&#x2013;536 <pub-id pub-id-type="pmid">11823860</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sotiriou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Neo</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>McShane</surname>
              <given-names>LM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2003</year>
          <volume>100</volume>
          <fpage>10393</fpage>
          <lpage>10398</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sotiriou C, Neo SY, McShane LM et&#xA0;al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393&#x2013;10398 <pub-id pub-id-type="pmid">12917485</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vijver</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>YD</given-names>
            </name>
            <name>
              <surname>Veer</surname>
              <given-names>LJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <fpage>1999</fpage>
          <lpage>2009</lpage>
        </citation>
        <citation citation-type="display-unstructured">van de Vijver MJ, He YD, van&#x2019;t Veer LJ et&#xA0;al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999&#x2013;2009 <pub-id pub-id-type="pmid">12490681</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Swensen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shattuck-Eidens</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1</article-title>
          <source>Science</source>
          <year>1994</year>
          <volume>266</volume>
          <fpage>66</fpage>
          <lpage>71</lpage>
        </citation>
        <citation citation-type="display-unstructured">Miki Y, Swensen J, Shattuck-Eidens D et&#xA0;al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66&#x2013;71 <pub-id pub-id-type="pmid">7545954</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robson</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Chappuis</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Satagopan</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment</article-title>
          <source>Breast Cancer Res</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>R8</fpage>
          <lpage>R17</lpage>
        </citation>
        <citation citation-type="display-unstructured">Robson ME, Chappuis PO, Satagopan J et&#xA0;al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8&#x2013;R17 <pub-id pub-id-type="pmid">14680495</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eerola</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vahteristo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sarantaus</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland</article-title>
          <source>Int J Cancer</source>
          <year>2001</year>
          <volume>93</volume>
          <fpage>368</fpage>
          <lpage>372</lpage>
        </citation>
        <citation citation-type="display-unstructured">Eerola H, Vahteristo P, Sarantaus L et&#xA0;al (2001) Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 93:368&#x2013;372 <pub-id pub-id-type="pmid">11433401</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrero</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ramaioli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Formento</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up</article-title>
          <source>Ann Oncol</source>
          <year>2000</year>
          <volume>11</volume>
          <fpage>393</fpage>
          <lpage>397</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ferrero JM, Ramaioli A, Formento JL et&#xA0;al (2000) P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol 11:393&#x2013;397 <pub-id pub-id-type="pmid">10847456</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haerslev</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis</article-title>
          <source>Hum Pathol</source>
          <year>1995</year>
          <volume>26</volume>
          <fpage>295</fpage>
          <lpage>301</lpage>
        </citation>
        <citation citation-type="display-unstructured">Haerslev T, Jacobsen GK (1995) An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 26:295&#x2013;301 <pub-id pub-id-type="pmid">7890281</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mirza</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Mirza</surname>
              <given-names>NQ</given-names>
            </name>
            <name>
              <surname>Vlastos</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5&#xA0;years</article-title>
          <source>Ann Surg</source>
          <year>2002</year>
          <volume>235</volume>
          <fpage>10</fpage>
          <lpage>26</lpage>
        </citation>
        <citation citation-type="display-unstructured">Mirza AN, Mirza NQ, Vlastos G et&#xA0;al (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5&#xA0;years. Ann Surg 235:10&#x2013;26 <pub-id pub-id-type="pmid">11753038</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="other">Fitzgibbons PL, Page DL, Weaver D et&#xA0;al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966&#x2013;78</citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berclaz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>KN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience</article-title>
          <source>Ann Oncol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>875</fpage>
          <lpage>884</lpage>
        </citation>
        <citation citation-type="display-unstructured">Berclaz G, Li S, Price KN et&#xA0;al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15:875&#x2013;884 <pub-id pub-id-type="pmid">15151943</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dignam</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wieand</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2003</year>
          <volume>95</volume>
          <fpage>1467</fpage>
          <lpage>1476</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dignam JJ, Wieand K, Johnson KA et&#xA0;al (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467&#x2013;1476 <pub-id pub-id-type="pmid">14519753</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dignam</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wieand</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2005</year>
          <volume>97</volume>
          <issue>3</issue>
          <fpage>245</fpage>
          <lpage>254</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dignam JJ, Wieand K, Johnson KA et&#xA0;al (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97(3):245&#x2013;254 <pub-id pub-id-type="pmid">16331345</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holmes</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Stampfer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Colditz</surname>
              <given-names>GA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dietary factors and the survival of women with breast carcinoma</article-title>
          <source>Cancer</source>
          <year>1999</year>
          <volume>86</volume>
          <fpage>826</fpage>
          <lpage>835</lpage>
        </citation>
        <citation citation-type="display-unstructured">Holmes MD, Stampfer MJ, Colditz GA et&#xA0;al (1999) Dietary factors and the survival of women with breast carcinoma. Cancer 86:826&#x2013;835 <pub-id pub-id-type="pmid">10463982</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byers</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sedjo</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>A weight loss trial for breast cancer recurrence: pre-menopausal, post-menopausal, both, or neither</article-title>
          <source>Cancer Causes Control</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>1</fpage>
          <lpage>3</lpage>
        </citation>
        <citation citation-type="display-unstructured">Byers T, Sedjo RL (2006) A weight loss trial for breast cancer recurrence: pre-menopausal, post-menopausal, both, or neither? Cancer Causes Control 17:1&#x2013;3 <pub-id pub-id-type="pmid">16411046</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holmes</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Feskanich</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Physical activity and survival after breast cancer diagnosis</article-title>
          <source>JAMA</source>
          <year>2005</year>
          <volume>293</volume>
          <fpage>2479</fpage>
          <lpage>2486</lpage>
        </citation>
        <citation citation-type="display-unstructured">Holmes MD, Chen WY, Feskanich D et&#xA0;al (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479&#x2013;2486 <pub-id pub-id-type="pmid">15914748</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Byers</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices</article-title>
          <source>CA Cancer J Clin</source>
          <year>2003</year>
          <volume>53</volume>
          <fpage>268</fpage>
          <lpage>291</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brown JK, Byers T, Doyle C et&#xA0;al (2003) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 53:268&#x2013;291 <pub-id pub-id-type="pmid">14570227</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kroenke</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>FB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dietary patterns and survival after breast cancer diagnosis</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>9295</fpage>
          <lpage>9303</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kroenke CH, Fung TT, Hu FB et&#xA0;al (2005) Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 23:9295&#x2013;9303 <pub-id pub-id-type="pmid">16361628</pub-id></citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <citation citation-type="other">Colditz GA (2005) Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11:909s&#x2013;917s</citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Closas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brinton</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Lissowska</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Established breast cancer risk factors by clinically important tumour characteristics</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>95</volume>
          <fpage>123</fpage>
          <lpage>129</lpage>
        </citation>
        <citation citation-type="display-unstructured">Garcia-Closas M, Brinton LA, Lissowska J et&#xA0;al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95:123&#x2013;129 <pub-id pub-id-type="pmid">16755295</pub-id></citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rylander-Rudqvist</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study</article-title>
          <source>Int J Cancer</source>
          <year>2006</year>
          <volume>119</volume>
          <fpage>1683</fpage>
          <lpage>1689</lpage>
        </citation>
        <citation citation-type="display-unstructured">Suzuki R, Rylander-Rudqvist T, Ye W et&#xA0;al (2006) Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer 119:1683&#x2013;1689 <pub-id pub-id-type="pmid">16646051</pub-id></citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rylander-Rudqvist</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2005</year>
          <volume>97</volume>
          <fpage>1601</fpage>
          <lpage>1608</lpage>
        </citation>
        <citation citation-type="display-unstructured">Suzuki R, Ye W, Rylander-Rudqvist T et&#xA0;al (2005) Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 97:1601&#x2013;1608 <pub-id pub-id-type="pmid">16264180</pub-id></citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takeuchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Baba</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kano</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The time-related changes of the importance of prognostic factors in breast cancer. A sequential multivariate analysis of 1423 Japanese patients</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2005</year>
          <volume>94</volume>
          <fpage>273</fpage>
          <lpage>278</lpage>
        </citation>
        <citation citation-type="display-unstructured">Takeuchi H, Baba H, Kano T et&#xA0;al (2005) The time-related changes of the importance of prognostic factors in breast cancer. A sequential multivariate analysis of 1423 Japanese patients. Breast Cancer Res Treat 94:273&#x2013;278 <pub-id pub-id-type="pmid">16261405</pub-id></citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zahl</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Tretli</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival of breast cancer in Norway by age and clinical stage</article-title>
          <source>Stat Med</source>
          <year>1997</year>
          <volume>16</volume>
          <fpage>1435</fpage>
          <lpage>1449</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zahl PH, Tretli S (1997) Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med 16:1435&#x2013;1449 <pub-id pub-id-type="pmid">9249917</pub-id></citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <citation citation-type="other">Liu S, Edgerton SM, Moore DH 2nd et&#xA0;al (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7:1716&#x2013;1723</citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>HK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>14&#xA0;years of follow-up from the Edinburgh randomised trial of breast-cancer screening</article-title>
          <source>Lancet</source>
          <year>1999</year>
          <volume>353</volume>
          <fpage>1903</fpage>
          <lpage>1908</lpage>
        </citation>
        <citation citation-type="display-unstructured">Alexander FE, Anderson TJ, Brown HK et&#xA0;al (1999) 14&#xA0;years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 353:1903&#x2013;1908 <pub-id pub-id-type="pmid">10371567</pub-id></citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yen</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Vitak</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <fpage>1405</fpage>
          <lpage>1410</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tabar L, Yen MF, Vitak B et&#xA0;al (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:1405&#x2013;1410 <pub-id pub-id-type="pmid">12727392</pub-id></citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>LY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of detection method in predicting breast cancer survival: analysis of randomized screening trials</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2005</year>
          <volume>97</volume>
          <fpage>1195</fpage>
          <lpage>1203</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shen Y, Yang Y, Inoue LY et&#xA0;al (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97:1195&#x2013;1203 <pub-id pub-id-type="pmid">16106024</pub-id></citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joensuu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lehtimaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Holli</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk for distant recurrence of breast cancer detected by mammography screening or other methods</article-title>
          <source>JAMA</source>
          <year>2004</year>
          <volume>292</volume>
          <fpage>1064</fpage>
          <lpage>1073</lpage>
        </citation>
        <citation citation-type="display-unstructured">Joensuu H, Lehtimaki T, Holli K et&#xA0;al (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064&#x2013;1073 <pub-id pub-id-type="pmid">15339900</pub-id></citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peto</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boreham</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>UK and USA breast cancer deaths down 25% in year 2000&#xA0;at ages 20&#x2013;69&#xA0;years</article-title>
          <source>Lancet</source>
          <year>2000</year>
          <volume>355</volume>
          <fpage>1822</fpage>
        </citation>
        <citation citation-type="display-unstructured">Peto R, Boreham J, Clarke M et&#xA0;al (2000) UK and USA breast cancer deaths down 25% in year 2000&#xA0;at ages 20&#x2013;69&#xA0;years. Lancet 355:1822 <pub-id pub-id-type="pmid">10832853</pub-id></citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnstone</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Norton</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Riffenburgh</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Survival of patients with untreated breast cancer</article-title>
          <source>J Surg Oncol</source>
          <year>2000</year>
          <volume>73</volume>
          <fpage>273</fpage>
          <lpage>277</lpage>
        </citation>
        <citation citation-type="display-unstructured">Johnstone PA, Norton MS, Riffenburgh RH (2000) Survival of patients with untreated breast cancer. J Surg Oncol 73:273&#x2013;277 <pub-id pub-id-type="pmid">10797344</pub-id></citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jeong</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Bryant</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>364</volume>
          <fpage>858</fpage>
          <lpage>868</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fisher B, Jeong JH, Bryant J et&#xA0;al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858&#x2013;868 <pub-id pub-id-type="pmid">15351193</pub-id></citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Darby</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>366</volume>
          <fpage>2087</fpage>
          <lpage>2106</lpage>
        </citation>
        <citation citation-type="display-unstructured">Clarke M, Collins R, Darby S et&#xA0;al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087&#x2013;2106 <pub-id pub-id-type="pmid">16360786</pub-id></citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jeong</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2004</year>
          <volume>96</volume>
          <fpage>1823</fpage>
          <lpage>1831</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fisher B, Jeong JH, Anderson S et&#xA0;al (2004) Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823&#x2013;1831 <pub-id pub-id-type="pmid">15601638</pub-id></citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hurley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Doliny</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>1831</fpage>
          <lpage>1838</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hurley J, Doliny P, Reis I et&#xA0;al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24:1831&#x2013;1838 <pub-id pub-id-type="pmid">16549824</pub-id></citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Romond</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Bryant</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <fpage>1673</fpage>
          <lpage>1684</lpage>
        </citation>
        <citation citation-type="display-unstructured">Romond EH, Perez EA, Bryant J et&#xA0;al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673&#x2013;1684 <pub-id pub-id-type="pmid">16236738</pub-id></citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ernst</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Voogd</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Coebergh</surname>
              <given-names>JW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Using loco-regional recurrence as an indicator of the quality of breast cancer treatment</article-title>
          <source>Eur J Cancer</source>
          <year>2004</year>
          <volume>40</volume>
          <fpage>487</fpage>
          <lpage>493</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ernst MF, Voogd AC, Coebergh JW et&#xA0;al (2004) Using loco-regional recurrence as an indicator of the quality of breast cancer treatment. Eur J Cancer 40:487&#x2013;493 <pub-id pub-id-type="pmid">14962713</pub-id></citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stefoski Mikeljevic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haward</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Surgeon workload and survival from breast cancer</article-title>
          <source>Br J Cancer</source>
          <year>2003</year>
          <volume>89</volume>
          <fpage>487</fpage>
          <lpage>491</lpage>
        </citation>
        <citation citation-type="display-unstructured">Stefoski Mikeljevic J, Haward RA, Johnston C et&#xA0;al (2003) Surgeon workload and survival from breast cancer. Br J Cancer 89:487&#x2013;491 <pub-id pub-id-type="pmid">12888817</pub-id></citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simunovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rempel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Theriault</surname>
              <given-names>ME</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario</article-title>
          <source>Can J Surg</source>
          <year>2006</year>
          <volume>49</volume>
          <fpage>251</fpage>
          <lpage>258</lpage>
        </citation>
        <citation citation-type="display-unstructured">Simunovic M, Rempel E, Theriault ME et&#xA0;al (2006) Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg 49:251&#x2013;258 <pub-id pub-id-type="pmid">16948883</pub-id></citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houterman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Janssen-Heijnen</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Poll-Franse</surname>
              <given-names>LV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis</article-title>
          <source>Ann Oncol</source>
          <year>2006</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>709</fpage>
          <lpage>712</lpage>
        </citation>
        <citation citation-type="display-unstructured">Houterman S, Janssen-Heijnen ML, van de Poll-Franse LV et&#xA0;al (2006) Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol 17(4):709&#x2013;712 <pub-id pub-id-type="pmid">16418307</pub-id></citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haerslev</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Zedeler</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>1996</year>
          <volume>37</volume>
          <fpage>101</fpage>
          <lpage>113</lpage>
        </citation>
        <citation citation-type="display-unstructured">Haerslev T, Jacobsen GK, Zedeler K (1996) Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37:101&#x2013;113 <pub-id pub-id-type="pmid">8750578</pub-id></citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaffney</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Brohet</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations</article-title>
          <source>Radiother Oncol</source>
          <year>1998</year>
          <volume>47</volume>
          <fpage>129</fpage>
          <lpage>136</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gaffney DK, Brohet RM, Lewis CM et&#xA0;al (1998) Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47:129&#x2013;136 <pub-id pub-id-type="pmid">9683359</pub-id></citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mansi</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Gogas</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bliss</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study</article-title>
          <source>Lancet</source>
          <year>1999</year>
          <volume>354</volume>
          <fpage>197</fpage>
          <lpage>202</lpage>
        </citation>
        <citation citation-type="display-unstructured">Mansi JL, Gogas H, Bliss JM et&#xA0;al (1999) Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197&#x2013;202 <pub-id pub-id-type="pmid">10421301</pub-id></citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Page</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Allred</surname>
              <given-names>DC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192)</article-title>
          <source>Am J Clin Oncol</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>10</fpage>
          <lpage>18</lpage>
        </citation>
        <citation citation-type="display-unstructured">Page DL, Gray R, Allred DC et&#xA0;al (2001) Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 24:10&#x2013;18 <pub-id pub-id-type="pmid">11232942</pub-id></citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houterman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Janssen-Heijnen</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Verheij</surname>
              <given-names>CD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients</article-title>
          <source>Br J Cancer</source>
          <year>2004</year>
          <volume>90</volume>
          <fpage>2332</fpage>
          <lpage>2337</lpage>
        </citation>
        <citation citation-type="display-unstructured">Houterman S, Janssen-Heijnen ML, Verheij CD et&#xA0;al (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 90:2332&#x2013;2337 <pub-id pub-id-type="pmid">15162155</pub-id></citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siegelmann-Danieli</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Khandelwal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>GC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach</article-title>
          <source>Clin Breast Cancer</source>
          <year>2006</year>
          <volume>7</volume>
          <fpage>59</fpage>
          <lpage>66</lpage>
        </citation>
        <citation citation-type="display-unstructured">Siegelmann-Danieli N, Khandelwal V, Wood GC et&#xA0;al (2006) Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach. Clin Breast Cancer 7:59&#x2013;66 <pub-id pub-id-type="pmid">16764745</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>